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A major problem with current cancer chemotherapy is the lack of 
selectivity of antitumor drugs. Most of the drugs exert various side effects such as 
hepatotoxicity, cardiotoxicity and neurotoxicity on the host. In order to reduce the 
adverse side effects on normal cells and to enhance the anti-tumor effects, the 
antitumor drugs would be linked to a specific carrier, such as hormones, antibodies or 
enclosed in liposomes before administrations. However, a problem in in vivo 
administration of such drug-carrier complexes is their rapid clearances, induction of 
immunological reactions, or instabilities. 
According to the previous studies, human leukaemic cells and certain 
tumor tissues display elevated low density lipoprotein (LDL) receptors as compared 
with the corresponding normal cells or tissues. Moreover, there have been a number 
of reports linking hypocholesterolemia and hypolipoproteinemia with various cancers. 
It is proposed that plasma LDL is taken up by LDL receptors on the tumor cells in the 
cancer patients. Therefore, LDL has been proposed as a potential carrier for antitumor 
drugs targeting towards the tumor cells. 
In this study, a method of incorporating doxorubicin (Dox) into LDL 
without altering its function by mixing LDL and Dox at 37°C for 24 hours in dark 
was used. The cytotoxicity effects of doxorubicin (Dox) and low density lipoprotein-
doxorubicin (LDL-Dox) on human hepatoma cells (HepG2) and human resistant 
hepatoma cells (R-HepG2) were examined. Results from the current studies suggested 
that in in vitro studies the anti-proliferative effect of LDL-Dox on HepG2 cells was 
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less than that of free Dox, i.e. the I C 5 0 of free Dox and LDL-Dox was 1.7|iM and 
8.9|j,M for 24 hours incubation respectively, and vice versa on R-HepG2 cells, i.e. the 
I C 5 0 of free Dox and LDL-Dox was 368|aM and 48)aM for 24 hours incubation 
respectively. 
In order to increase the cytotoxicity effect of LDL-Dox complex on 
tumor cells, an alkaline extract (O.IN NaOH) from Fructus Crataegus (FC), a 
Traditional Chinese Medicine, was used to examine the possibility of elevating the 
expression level of LDL receptors on HepG2 cells and R-HepG2 cells. The 
expression level of LDL receptors was found to be higher under FC treatment in 
HepG2 cells but not in R-HepG2 cells as compared with control. Moreover, the 
cytotoxic effect of LDL-Dox on HepG2 cells was enhanced after the pre-treatment of 
FC, i.e. the I C 5 0 of LDL-Dox with and without FC pre-treatment was 0.6|iM and 
8.9)aM respectively. 
In addition, the combined treatment of hyperthermia and antitumor 
drugs could enhance the anti-proliferative of free Dox and LDL-Dox on HepG2 cells 
and R-HepG2 cells. Hyperthermia could increase the intracellular level of free Dox in 
cells which led to more cytotoxicity to the tumor cells. Although hyperthermia could 
not increase the intracellular level of LDL-Dox in cells, the anti-proliferative effect of 
LDL-Dox was enhanced because hyperthermia altered the metabolic rate on the tumor 
cells in which the contact of Dox released from LDL-complex was increased. 
In in vivo studies, the anti-proliferative effect of LDL-Dox was higher 
than that of free Dox on nude mice bearing human resistant hepatoma R-HepG2 cells. 
- i i -
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However, the adverse effect of the LDL-Dox on the heart of tumor-bearing nude mice 
was alleviated comparing with that of free Dox. It was indicated that after Dox is 
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CHAPTER 1 : INTRODUCTION 
1.1. DIFFERENT TREATMENTS OF THE CANCER 
THERAPY 
Surgery, radiotherapy, and chemotherapy are all effective treatments 
for cancer and they have been used alone or in a combined treatment. Surgery and 
radiotherapy can often eradicate primary or localized disease but may ultimately fail 
because of the metastasized characteristic of the cancer. In such instances, if 
chemotherapy is used properly, it will control or eliminate metastatic disease and 
reduce mortality. When chemotherapy combined with surgery or radiotherapy or 
both, it is usually called an adjuvant therapy. Moreover the adjuvant therapy can 
increase the survival rates for a number of solid tumors that were formerly treated by 
only one therapy. 
1.2. THE SIDE EFFECTS OF CANCER TREATMENT 
1.2.1. Surgery 
Surgery can be a curative therapy only when the tumor is confined to 
an anatomical region. It is a way of removing a visible tumor to cure the disease. 
Surgery can relieve pain and treat complications, which are causing uncomfortable 
symptoms. Moreover, it would increase the effectiveness of radiation and 
- 1 -
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chemotherapy. But surgery would remove an area of normal-looking tissue 
surrounding the tumor to ensure that no cancer cells remain in the immediate 
vicinity. Also, there is a high risk for old people since it might cause death. 
1.2.2. Radiotherapy 
Radiotherapy is a method using the high energy to damage the cancer 
cells，DNA in order to make them less able to reproduce. Since cancer cells divide 
more quickly than those of healthy cells, they are more vulnerable to radiation. Also 
some tumors are more susceptible to radiation, such as nasopharyngeal carcinoma. 
Although radiotherapy could take a part in treatment of cancer, some 
side effects often occur, such as poor appetite and skin problems. Furthermore, 
radiodamage does not distinguish between cancer cells and healthy proliferative 
cells, so the patients need special protection during the therapy. 
1.2.3. Chemotherapy 
Chemotherapy is a systemic treatment because it treats cancer which 
is growing inside the body. There are more than fifty anticancer drugs now in use for 
this therapy. Moreover, the anticancer drugs could destroy rapidly dividing cells or 
prevent them from proliferation. The most common use for chemotherapy is the 




But most of the anticancer drugs are lack of selectivity between 
cancer cells and normal cells, so they may lead to severe toxic effects on normal cells 
(Table 1.2). Moreover, after a long term treatment, the cancer cells would be 
developed into multidrug resistant cancer cells. 
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Table 1.1: Diseases in which chemotherapy have contributed to a life-span 
approaching normal life expectancy (Johnson et al., 1975). 
Disease Regimen 
Burkitt's lymphoma Cyclophosphamide ~~ 
Choriocarcinoma Methotrexate; actinomycin D 
Acute lympocytic leukemia of childhood Vincristine and prednisone for 
induction; methotrexate, 6-MP for 
maintenance; vincristine, prednisone, 6-
mercaptopurine, methotrexate 
Hodgkin's disease Nitrogen mustard, vincristine, 
procarbazine and prednisone 
Lymphosarcoma Cyclophosphamide, vincristine and 
prednisone 
Embryonal teaticular carcinoma Actinomycin D， mithramycin, 
vincristine, methotrexate, bleomycin, 
vinblastine and cw-platinum 
Wilm's tumor Surgery, radiotherapy, actinomycin D 
and vincristine 
Swing's sarcoma Radiotherapy, vincristine and 
cyclophosphamide 
Rhabdomyosarcoma Surgery, radiotherapy, vincristine, 
cyclophosphamide and actinomycin D 
Retinoblastoma Radiotherapy and cyclophosphamide 
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Table 1.2: Clinical undesirable effect of anticancer drugs. 
Tissue or system affected Toxic effects 
Bone marrow Leukopenia and lyphocytopenia with an increased 
risk of infection or activation of quiescent 
infection; 
Immunosuppression; 
Thrombocytopenia leading to hemorrhage; 
Anemia. 
Digestive tract Oral ulceration; 
Intestinal ulceration, diarrhea. 
Hair root Alopecia. 
Gonads Menstrual irregularities, ammenorrhea; infertility. 
Impaired spermatogenesis; sterility. 
Tissues undergoing repair Impaired healing, 
(surgical wounds, etc) 
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1.3. THE CHARACTERISTICS OF DOXORUBICIN 
(DOX) 
1.3.1. The structure of Dox 
Doxorubicin (Dox) is one of the prototypes of anthracycline 
anticancer antibiotic with anti-tumoral activity which is isolated from strains of 
Streptomyces peucetius. Dox is currently in widespread clinical used. The chemical 
structure of these antibiotics includes an aglycone chromophore with four fused rings 
and an amino sugar，daunosamine (Fig. 1.1). 
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Fig. 1.1. Structure of Doxorubicin. 
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1.3.2. The actions of Dox 
Doxorubicin (Dox) is a common and powerful anticancer drug in 
chemotherapy. It can treat a wide variety of solid tumors, such as carcinoma of liver, 
breast，lung; soft tissue sarcomas and many cancers of blood. Moreover, the multiple 
potential mechanism actions of anthracycline include inhibition of DNA 
topoisomerase I (Fogleson et al, 1992) and II (Tewey et a/., 1984)，inhibition of 
helicases (Bachur et al., 1992), generation of free radicals through the 
monoelectronic reduction of the anthracyclinic ring (Bachur et al., 1977)，altertion of 
membrane structure and function (Koseki et al” 1991)，and exhibition of 
endonucleolytic clevage (Ling et al” 1993). 
1.3.3. The adverse side effect of Dox 
Although Dox is currently used in clinical treatment, the limitation of 
Dox is that it may cause a potentially lethal and dose-dependent congestive heart 
failure which finally results in cardiomyopathy. The mechanism of Dox-induced 
cardiomyopathy is unclear, but most of the evidence suggested that free radicals 
mediated damage are involved. The chemical structure of Dox is prone to the 
generation of free radicals (Sinha et aL’ 1987)，and the cellular injury is caused by 
oxidative stress (Rosen et aL, 1990). When the oxidative stress is increased, it may 
lead to a variety of subcellular changes in the myocardium, such as the slow loss of 
myofibrils and vacuolization of myocardial cells. In addition, the administration of 
Dox is associated with the decrease in the presence of the endogenous antioxidants 
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which are responsible for the scavenging of free radicals (Singal et al” 1995). Thus, 
the decrease of antioxidants and the increase of oxidant (free radicals) will increase 
the oxidative stress, which will result in the development of cardiomyopathy and 
heart failure (Singal et al.’ 1997). 
In addition, the immediate side effects of Dox treatment are reversible 
or clinically manageable, such as myelosuppression, nausea, vomiting and 
arrhythmia (Lefrak et al., 1973). 
1.4. THE RATIONALE OF USING LOW DENSITY 
LIPOPROTEIN (LDL) AS A TARGET CARRIER IN 
CANCER THERAPY 
1.4.1 The correlation between cholesterol and cancer 
There have been a number of reports which found that 
hypocholesterolemia and hypolipoproteinemia are usually found in patients bearing 
various cancers, such as leukaemia (Alexopoulos et al., 1987). Several 
epidemiological studies have shown a correlation between low plasma cholesterol 
levels and the appearance of cancers (Feinleib M，1983). However, it is unclear 
whether low plasma cholesterol is a risk factor for the development of malignancy or 
secondary to the existence of cancer (Vitols et al” 1991). Regarding the risk factor 
for the development of malignancy, one factor may be an increase in the biliary 
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sterols excretion due to hypocholesterolemia which could then be metabolized by 
bacteria in the gut in order to increase the production of carcinogenic sterols (Reddy 
et al, 1981). A number of studies in patients with different cancers demonstrated that 
low serum cholesterol levels were usually found in their blood samples (Cambien et 
al., 1980). 
In 1939，Muller (1939) noted that patients with leukaemia commonly 
exhibited hypocholesterolaemia. Some reports showed that most of the acute 
myelogenous leukemia patients (AML) have higher low density lipoprotein receptor 
(LDL-R) activity of leukaemic cells when compared with those from the healthy 
subjects (Ho et al” 1978). It may be due to the increased uptake of cholesterol by 
leukaemic cells. These reports also indicated an inverse correlation between 
cholesterol concentration and the activity of low density lipoprotein receptors in 
leukaemic cells. The reason for the higher LDL receptor activity in leukaemic cells 
remains unknown, and may be due to the enhancement of membrane synthesis by the 
proliferating cells (Klock et al., 1979). During chemotherapy, the serum cholesterol 
levels increase concomitantly with the decrease of the number of leukaemic cells. 
In the recent studies of the prostatic carcinoma, as the cancer patients 
are in the metastasis phase, their serum cholesterol levels are significantly lower than 
that in patients who are not in the metastasis phase (Henriksson et al., 1989). 
In addition, a case report demonstrated that a patient bearing adrenal 
adenoma exhibited severe hypocholesterolemia. The increased of LDL receptor 
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activity and the uncontrolled uptake of LDL by the tumor cells are the result of the 
hypocholesterolemia. But the serum cholesterol levels rose dramatically after the 
resection of the adrenal tumor in this patient (Nakagawa et al, 1994). 
1-4.2. Low density lipoprotein (LDL) as a target carrier 
The major problem with the current cancer chemotherapy is that the 
anticancer drugs are often limited by their inability to discriminate between normal 
cells and cancer cells, inducing severe toxic effects on normal cells rather than on 
cancer cells. One way to enhance the specificity of the anticancer drugs is to link 
them to a carrier which is specifically taken up by the tumor cells. One carrier that 
has recently stimulated interest is low density lipoprotein (LDL) because the tumor 
cells display elevated low density lipoprotein receptor mediated uptake of LDL 
comparing with the normal cells (Fig. 1.2). 
LDL is a component of plasma whose physiological function is the 
transport of cholesterol. LDL can administer the highly lipophilic compounds. 
Moreover, the core of LDL provides spacing for drugs sequestration in order to 
isolate them from serum enzyme and water (Vitols et al, 1990). LDL is a 
physiological carrier that is not easily cleared by the reticuloendothelial system. The 
serum half-life of anticancer drugs can be prolonged when they are incorporated into 
LDL (De Smidt et al” 1990). Also, LDL can be internalized and degraded by LDL 
receptor pathway in cancer cells. This highly effective process could lead to different 
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pharmacological effects, such as circumvention of some drug resistance mechanism 
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1.4.3. The down and up regulation of LDL receptors 
Although it is important to deliver LDL-drugs only to the tumors and 
exclude them from reducing the normal tissues, some tissues and organs such as liver 
and adrenal could also compete to uptake the drug complex. Thus, protection of these 
tissues and organs is desirable when LDL-drugs are administered to the patients. 
Some reports found that after feeding the tumor bearing mice with 
sodium taurocholate and hydrocortisone sodium succinate, the uptake of LDL by 
liver and adrenal was reduced, but the uptake of LDL by the tumor did not have a 
significant reduction (Hynds et al., 1984). A report demonstrated that saturated fats, 
cholesterol with hydrogenated coconut oil and fasting could down-regulate the LDL 
receptors on normal cells, but not the tumor cells (Shimano et al., 1988). 
On the other hand, it is crucial to elevate the LDL receptors on the 
tumor cells, but not on normal cells in order to increase the uptake of LDL-drug 
complex. There are some chemicals and hormones which can up-regulate the LDL 
receptors in tumor cells, such as taurine (Zouhair et al, 1987), insulin (Nagels et al., 
1997)，estrogen, thyroid hormone and glucagons (Parini et al” 1995), troglitazone 
(Rayyes et al., 1998) and Fructus Crataegus (Wilmar S, 1960). 
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1.4.4. The characteristics of Fructus Crataegus (FC) 
Fructus Crataegus (FC) is the Crataegus pinnatifida Bunge. var. major 
N. E. Br. Reports showed that the extraction of FC can lower the serum cholesterol, 
especially low density lipoprotein (LDL) and very low density lipoprotein (VLDL) 
(Chu, 1988). Also FC can increase the activity of superoxide dismutase (SOD) and 
reduce the activity of monoamine oxidase (MAO). The components of FC such as 
hyperoside, epicatechin, rutin and quercitin can reduce the serum cholesterol level 
(Sit et al., 1985). 
In this project, the crude extract of FC is used to investigate the up-
I 
regulation of LDL receptor on tumor cells. The crude extract of FC consists of eight 
pure compounds; they are ursolic acid, protocatechuic acid (Fig. 1.3)，quercitin, 
epicatechin, hyperoside, isoquercitrin, chlorogenic acid and rutin (Fig. 1.4). 
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1.5. DIFFERENT METHODS OF THE PREPARATION 
OF THE LOW DENSITY LIPOPROTEIN-DRUG 
(LDL-DRUG) 
In order to kill tumors with drugs that are targeted to the LDL 
receptors, the drugs must first be bound to LDL. When this drug-complex is traveling 
in the blood, it should not be dissociated. Moreover, its cytotoxicity should be 
restored after entering into the tumor cells. 
The first published paper concerning the procedure of LDL-drug 
synthesis was reported by Krieger et al” (1979), in which hydrophobic compound is 
incorporated into native LDL. The LDL was isolated, lyophilized in the presence of 
potato starch and the core of LDL was delipidated by heptane extraction. Then the 
heptane-extracted LDL was reconstituted by adding the drug which was dissolved in 
the nonpolar solvent. Finally, the solvent was evaporated and the reconstituted LDL 
was replaced with aqueous buffer. Although the carrying power of the reconstituted 
LDL was high, the entire core is replaced which may lead to leakage of the drug 
from reconstituted LDL or failed to reconstitute altogether. Moreover, the creation of 
aggregated reconstituted LDL would by rapidly cleared by the reticuloendothelial 
system. 
In the method of Masquelier et al., (1986), the LDL was lyophilized 
in the presence of sucrose as protecting agent and the core of LDL was not discarded. 
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The pharmacokenetics of reconstituted LDL was found to be more closely to the 
native LDL, but the drug carrying power was lower when comparing with the 
method of Krieger et. al (1979). Also, this method was easier for reconstitution 
without aggregation. 
In the method of Lundburd (1984)，LDL is delipidated by a detergent 
(sodium deoxycholate, SDOC), then the apoprotein B is resonstituted with the drug 
and egg phosphatidyl choline (EPC) into a microemulsion. The LDL-drug was 
isolated by ultracentrifugation through a sucrose gradient. Moreover, the yield and 
carrying powder of the LDL drug from this method was higher than that of the LDL-
drug formed from other methods. Also, the structure of the LDL-drug comlplex was 
similar to that of the native LDL. 
In the method of Rudling et a l , (1983)，the procedure was very simple 
and that LDL was singly mixed up with the drug. The LDL was incubated with an 
excess amount of the drug, then using the gel filtration method to separate the LDL-
drug and free drug from the mixture. In addition, the drug can be chemically linked 
to LDL and the leakage will not occur in this method. But the carrying power is 
limited and the cytotoxicity of the LDL-drug may be lower unless it is released 
efficiently after endocytosis (Vitols et al； 1984). 
The method used in this project is the aforesaid simple mixing 
technique to incorporate doxorubicin (Dox) into LDL (Rudling et al., 1983). The 
excess amount of Dox was used to incubate with LDL at 37°C for 24 hour and free 
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Dox was separated from LDL-Dox complex by gel filtration. In addition, Rudling et. 
al (1983) and Iwanik et. al (1984) have also used this method to incorporate other 
drugs into LDL. The advantage of this method is that the procedure is very simple 
and does not alter the structure of the LDL, thus the pharmacokenetics of LDL-drug 
complex is very close to that of the native LDL. 
1.6. THE CHARACTERISTICS OF LOW DENSITY 
LIPOPROTEIN (LDL) 
Cells may obtain cholesterol in two ways: by endogenous synthesis 
through de novo pathways or by the uptake of cholesterol-containing particles, 
namely lipoproteins, from the environment. The major cholesterol-carrying particle 
in human plasma is low density lipoprotein (LDL). In healthy individuals, the half-
life of the LDL in plasma is about 2 to 3 days. 
1.6.1. The structure of LDL 
LDL is a large spherical particle that has a molecular weight of 
approximately 3 x 10^ Dalton and the diameter is 22nm (Krieger et al, 1979). In each 
LDL particle, the core contains about 1500 molecules of cholesterol esterified with 
long-chain fatty acids such as oleate or linoleate. A shell of phospholipids and 
unesterified cholesterol surrounds the highly hydrophobic core. The phospholipid is 
mixed with unesterified cholesterol, presumably as a stabilizer and also a single 
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molecule per LDL particle of apoprotein B which bind to the specific cell surface 
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Fig. 1.5. Structure of low density lipoprotein (LDL) (Lehninger, 1993) 
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1.6.2. The metabolic pathway of LDL in human bodies 
Cells acquire cholesterol for membrane synthesis primarily through 
the adsorptive endocytosis of plasma LDL. The initial step in this uptake process is 
the high affinity binding of LDL to the cell surface receptors — LDL receptor 
followed by internalization and lyosomal degradation of the lipoprotein particle. 
Since each LDL particle has a single molecule of apoprotein B that 
can interact with the LDL receptors. After LDL binds to the LDL receptors, the 
bound LDL is taken into the cells by incorporation into endocytotic vesicles. Then 
the interiorized vesicles fuse with lysosomes. Lysosomal enzymes hydrolyze the 
protein and cholesterol ester components of LDL as the apoprotein B is degraded to 
amino acids and the liberated free cholesterol is transferred to cell membranes 
(Brown et aL, 1975). Cellular cholesteryl ester formation is stimulated and 
cholesterol synthesis is suppressed by the mechanisms involving the membrane-
bound enzymes, fatty acyl CoA: cholesteryl acyltransferase，and 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG CoA reductase). The entire system 
fimctions as a means of obtaining controlled access to cholesterol brought to the cell 
as plasma LDL. The system controls LDL cholesterol entry by controlling synthesis 
of LDL receptors via a feedback loop (Fig. 1.6). 
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1.7. THE MULTIDRUGS RESISTANCE IN TUMOR 
CELLS 
Resistance to the anticancer drugs in cancer cells is one of the major 
problem of the chemotherapy. Some tumors are intrinsically resistant to the 
treatments, that means the tumors fail to respond to the first chemotherapy given. 
Others are acquired multidrug resistance, that means at the beginning the tumors 
respond to the chemotherapy but they exhibit no response of the treatment at the 
latter stage, to a variety of structurally and unrelated drugs, such as anthracyclines, 
vinca alkaloids, epipodophyllotoxins, taxanes and actinomycin D (Table 1.3). These 
tumor cells are known to develop into multidrug resistance. 
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1.7.1. The mechanism of multidrug resistance 
The potential resistance mechanisms are the mutlidrug resistance 
(MDR) phenotype and mutlidrug resistance-associated protein (MRP). The MDR 
phenotype is related to a membrane-associated P-glycoprotein (P-gp) encoded in 
human cells by the MDR 1 gene which is located at the chromosome 7 (Roninson et 
a/” 1986)，and confers cross-resistance to a broad spectrum of drugs, such as 
anthracyclines. In addition, the MRP pump, which is the membrane-associated efflux 
mechanism, is able to extrude drugs from the cells against the concentration gradient. 
Moreover, MRP action is not significantly affected by the reversing agents, such as 
verapamil or cyclosporin A (Barrand et al., 1993). 
In addition, the drug resistance occurs through different mechanisms: 
increasing the activity of enzymes, such as glutathione-S-transferase (Morrow et al., 
1990)，glutathione peroxidase (Kramer et al., 1988), superoxide dismutase 
(Doroshow et al” 1991)，and altering the activity of topoisomerase II (Kim et al., 
1991) or hexose phosphate metabolism (Yeh et al., 1987). 
1.7.2. The structure of P-glycoprotein 
P-glycoprotein (P-gp) is a member of the large ATP-binding cassette 
superfamily of transport protein also called traffic ATPases (Pietro et aL, 1999). P-gp 
is a 170-kDa plasma membrane protein and an integral membrane protein of 1280 
amino acids arranged into two homologous halves, “ each containing six 
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transmembrane domains and an ATP binding domain, separated by a flexible linker 
polypeptide (Jone et al., 1998). The pore size of P-gp is 5nm. ATP 
binding/utilization and hydrolysis appear to be essential for the proper functioning of 
P-gp, including the role as a drug transport (Horio et al., 1988) (Fig. 1.7). 
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Fig. 1.7. Structure of P-glycoprotein (Gottesman et al., 1988). 
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1.7.3. The mechanism of P-glycoprotein 
Although several models for P-glycoprotein (P-gp) function have 
been proposed, there is still no clear understanding at a molecular level of how the 
multidtrug transporter lowers intracellular accumulation of anticancer drugs. 
P-glycoprotein (P-gp) exists in several normal tissues in which it 
probably has a physiological role in elimination of xenobiotics and in protecting 
important tissues from some endogenous metabolites when they are in the blood 
(Cardo et al” 1989). Cancer cells seem to exploit this function to protect themselves 
from many cancer drugs. Therefore, P-gp could exert active drug efflux out of 
mutlidrug resistant cells in order to reduce accumulation of the drugs, which are 
prevented from reaching their cellular targets. 
Roepe et al (1997) proposed that overexpression of the P-gp could 
alter the electrical membrane potential and intracellular pH and other biophysical 
characteristics of the tumor cells. These alterations in the biophysical parameters of 
the tumor cells then perturbed the intracellular level of anticancer drugs. Thus, P-gp 
indirectly promotes decreased intracellular drug accumulation. 
Gottesman (1988) proposed a pump model of P-gp to explain the 
function of the drug transporter. The energy of ATP hydrolysis by P-gp is utilized for 
the removal of drugs from cell membranes and cytoplasm analogous to the ion-
translocating pumps. After the pump recognizes substrates through a complex 
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substrate recognition region, it would directly pumps drugs out of the cell by using 
molecular mechanisms, but the mechanisms are still unknown. 
1.8. COMBINED TREATMENT WITH 
HYPERTHERMIA 
Combined treatment is the combination of two or more individual 
treatments in order to increase the effectiveness of the treatments; also the toxic side 
effect of each individual treatment can be minimized. The effects of combined 
treatment can be additive, i.e. the total effect is equal to the summation of the 
individual effects. It can also be synergistic, i.e. the combined effect is larger than the 
summation of the individual effects. However, it may be partially additive, i.e. the 
combined effect is less than the summation of the individual effects. This may be due 
to the individual agents exhibit their effects by the same mechanism. 
Hyperthermia is commonly used to combine with chemotherapy or 
radiation as an adjunct cancer therapy. It is because the amount of anticancer drugs 
or the dosage of radiation can be reduced when hyperthermia is used together. The 
adverse side effects from chemotherapy and radiotherapy also can be reduced when 
combined with hyperthermia. 
The biophysical effects of hyperthermia remain unknown, but it may 
denature membrane protein (Lepock et al,, 1982), increase neovascular permeability 
(Gnant et al., 1999), and perturbation of multimolecular complexes (Calderwood et 
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al., 1983). Tumor cell inactivation is time and temperature dependent which starts at 
40 -41°C. Moreover, human tumor cell lines are more sensitive to mild hyperthermia, 
i.e. around 41 - 42°C (Armour et al., 1993). 
The solid tumor is sensitive to hyperthermia because of the 
susceptible microenvironment with low pH，low oxygen tension, low glucose and the 
loss of adaptive vasodilatation in response to heat. 
As the chemotherapy is combined with hyperthermia, the antitumor 
effect of various anticancer drugs is enhanced, such as doxorubicin, mitomycin C, 
cisplatin. It may be due to the increase of cell membrane permeability, the alteration 
of drug transport activity and the alteration of cell metabolism. Moreover, 
hyperthermia can decrease tumor tissues interstitial fluid pressure, enhance 
convection-driven macromolecular drug delivery (Leunig et al” 1992). But 
hyperthermia could induce the expression level of multidrug resistance gene (MDR 
1)，consequently the multidrug-resistant phenotype is developed. 
In addition, when hyperthermia is combined with radiotherapy, it also 
enhances the effectiveness of radiotherapy on the tumors. It can be explained that 
hyperthermia is cytotoxic to the cells which are under an environment with low 
partial pressure of oxygen and pH (Overgaard et al； 1989). Also when the 
hyperthermia is applied at a mild temperature, it can induce the reoxygenation of the 
cancer cells in order to make them more sensitive to radiation (Shakil et al.’ 1999). 
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1.9. AIM OF THE STUDY 
Antitumoral drugs always exhibit adverse side effects on normal cells 
because of the lack of the selectivity. Moreover, the drug resistance is usually a 
problem in chemotherapy. So there has been an urgent need to develop a target 
carrier for antitumoral drugs in order to increase drugs' specificity to tumor cells, 
decrease their toxicity to normal cells and circumvent multidrug resistance in tumor 
cells. 
The aim of this study was to investigate whether low density 
lipoprotein (LDL) can be used as a target carrier because the current studies 
demonstrated that the tumor cells express high density of low density lipoprotein 
receptor (LDL-R) on the membrane of the tumor cells. Thus this approach may be 
more specific to deliver antitumoral drugs to the tumor cells in order to decrease the 
cytotoxic effect on normal cells. Also it may overcome the efflux of antitumoral 
drugs by P-glycoprotein on resistant cell lines. Moreover, Fructus Crataegus (FC) is 
used to investigate the up-regulation of LDL-R on tumor cells in order to enhance the 
accumulation of LDL-drug complexes. Also using combined treatment strategy to 
investigate whether hyperthermia can enhance the cytotoxic effect of LDL-drug 
complexes. The cell line used in the study is human hepatoblastoma cells (HepG2 
cells) and human resistant hepatoblastoma cells (R-HepG2 cells). For the 
investigation in this study, doxorubicin (Dox) was used because Dox is a common 
antitumoral drug in chemotherapy. 
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CHAPTER 2 : MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. Animals 
Protocols relating to animal studies in this thesis have obtained the 
approval of the Animal Research Ethics Committee, The Chinese University of Hong 
Kong. Nude mice aged 6 - 8 weeks were bred at the Laboratory Animal Service 
Center of The Chinese University of Hong Kong under pathogen-free condition. 
Nude mice were kept in autoclaved cage with polyester fiber filters to avoid contact 
with the pathogens. All the animal diet (PICO LAB® Rodent Diet) and tape water 
were autoclaved before feeding to nude mice ad libitum. 
2.1.2. Buffers 
Phosphate buffered saline (PBS) 
It was prepared by mixing of 136mM NaCl, 2.7mM KCl, 1.5mM 
KH2PO4 and 8mM Na2P04. The solution was titrated to pH7.4 and steriled by 
autoclave and stored at room temperature. 
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Normal saline 
It was prepared by dissolving 9g of NaCl into 1 liter of the double 
distilled water and steriled by autoclave. It was stored at 4°C. 
Tris-buffer saline (TBS) 
It was prepared by dissolving 1.2114g Tris and 8.766g NaCl into 1 
liter of double distilled water. The solution was titrated to pH 8.0 and stored at room 
temperature. 
10% buffer formalin 
It was prepared by mixing of 900ml double distilled water, 100ml 
formalin, 8.5g NaCl, 4g NaH2P04 •2H2O and 6.5g NazHPO*. The solution was 
stored at room temperature. 
Harris hematoxylin 
It was prepared by mixing of hematoxylin Power, sodium iodate, 
ammonium atum, ethanol and double distilled water. The solution was stored at room 
temperature. 
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0.5% Eosin, Aqueous 
It was prepared by mixing of 200ml double distilled water, Ig eosin y, 
acetic acids and 2 - 3 drops of glacial. The solution was stored at room temperature. 
Scott's tap water 
It was prepared by dissolving 2g potassium carbonate, 20g 
magnesium sulphate into 100ml double distilled water and the solution was stored at 
room temperature. 
1% Acid Alcohol 
It was prepared by mixing of 1ml conc. HCl and 99ml 70% ethanol. 
The solution was stored at room temperature. 
2.1.3. Cell Culture Reagents 
Roswell Park Memorial Institute tissue culture medium 1640 (RPMI 1640 
medium) 
It was purchased from GibcoBRL Life Technologies Inc. and was 
used for cell culture experiment. Each pack of RPMI 1640 powder medium 
containing phenol red, L-glutamine and 0.5mM HEPES. The medium powder was 
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dissolved in 1 liter of double distilled water and was supplemented with 2g of 
sodium bicarbonate (NaHCOs). The pH of the medium was adjusted to 7.2. Finally, 
the medium was filtered by 0.22)^m bottle-top filter which was purchased from 
Millipore Company. 
The complete RPMI 1640 medium was added with 1% penicillin-
streptomycin (v/v) and 10% fetal bovine serum (FBS) (v/v). When the cells were 
treated with Doxorubicin coupled with LDL, 10% Lipoprotein deficient fetal bovine 
serum (LPDS) was used instead of using 10% of FBS. 
Fetal Calf Serum (FBS) 
It was purchased from GibcoBRL Life Technologies Inc. and was 
stored at-20°C. 
Lipoprotein deficient fetal bovine serum (LPDS) 
It was purchased from Sigma Chemical Company and was stored at -
20�C. 
Penicillin-streptomycin (PS) 
It was purchased from GibcoBRL Life Technologies Inc and was 
stored at-20°C. 
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2.1.4. Chemicals 
Doxorubicin (Dox) 
It was purchased from Sigma Chemical Company. A lOmg/ml stock 
solution of doxorubicin was made in autoclaved double distilled water and stored at -
20°C. This doxorubicin was used both in cell culture and animal tests. When 
doxorubicin was used to couple with LDL, it was also dissolved in autoclaved double 
distilled water at the concentration of 10 mg/ml and stored at —20�C. 
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazoliuin bromide (MTT) 
It was purchased from Sigma Chemical Company and was dissolved 
in IX PBS at the concentration of 5 mg/ml. The solution was then passed through a 
0.22|am millipore filter (Millipore Company) and stored at 4°C. 
Low density lipoprotein (LDL) 
It was purchased from Sigma Chemical Company, and according to 
the manufacturer, this LDL was isolated from plasma by using the modified methods 
of Rudel et. al, (1974) and Fellin et. al, (1974). It was concentrated and dialyzed 
extensively against 0.15 M NaCl，0.01% EDTA, pH 7.4 - 7.5. It was then filtered 
through a 0.2}am membrane. Its composition is 22% of protein and 78% of lipid. The 
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protein concentration varies from 5 mg/ml to 6.5 mg/ml. Its molecular weight is 3.5 x 
106 with diameter 22nm (Burstein, M. et. al, 1977). 
Acidified isopropanol 
It was prepared by dissolving 0.75M HCl in 90% isopropanol and 
stored at room temperature. 
Fructus Crataegus (FC) 
It was provided by Prof. Walter Ho's Laboratory, Department of 
Biochemistry, The Chinese University of Hong Kong. It was dissolved in double 
distilled water and the solution was titrated to pH 7.0. Then the solution was boiled at 
water bath for 15 minutes for the sterilization. Before using in cell culture, the 
solution was centrifuged at 2200x g for 5 minutes. 
Antibodies 
For Western blot analysis, Low Density Lipoprotein Receptor (LDL-
R)，primary antibody against LDL-R were purchased from Calbiochem. The 
secondary antibody, horse-radish peroxidase conjugated anti-mouse antibody were 
purchased from Amersharm Pharmacia Biotech. For P-glycoprotein analysis, 
primary antibody against P-glycoprotein was purchased from Calbiochem. The 
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secondary antibody, horse-radish peroxidase conjugated anti-rabbit antibody used 
was purchased from Santa Cruz Biotechnology, Inc. 
2.1.5. Culture of cells 
Differentiated Hepatoblastoma cell line (HepG2 cells) 
It was purchased from American Type Culture Collection (ATCC, 
Rockville, MD, USA). According to producer, this cell line was derived from a liver 
tumor biopsy obtained during extended lobectomy of a 15-year-old Caucasion male 
from Argentina (Aden et. al., 1979). The liver tumor was diagnosed histologically as 
a well-differentiated hepatoblastoma. Cells were maintained in RPMI 1640 medium 
and supplemented with 10% FBS and 1% penicillin-streptomycin (complete RPMI). 
They were cultured at 37°C, 5% CO2 incubator with humidified atmosphere. Cells 
were grown at culture flask and kept to pass every 3 or 4 days. For every passage, 
medium was discarded and washed once with PBS. Cells were trypsinized. The cell 
suspension was collected after addition of the complete medium to stop the 
trypsinization. This suspension was centrifuged at 300x g for 3 min. The pellet was 
resuspended with complete medium. Cells at 5 x cells/ml were passed to a new 
tissue culture flask. 
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Development of doxorubicin resistant hepatoma cell line (R-HepG2 cells) 
This resistant cell line was developed in our laboratory by incubating 
the HepG2 cells in stepwise increased concentrations of doxorubicin. After HepG2 
cells were grown to about 80% confluence, they were treated with doxorubicin at the 
concentration, which caused 90% of cell death with 48 hours incubation, namely 
0.1 liM. After incubating 24 hours with doxorubicin, the cells were washed several 
times with PBS and then incubated in fresh medium for another 24 hours. The cells 
were washed several times again with PBS and then incubated with fresh medium. 
This washing procedure was repeated until the cells grew to confluence. Cells were 
trypsinized and divided into two new flasks. After the cells grown to 80% of 
confluence, 0.2)iM of doxorubicin was incubated with the cells. The aforesaid 
treatments were repeated until the cell grew at 1.2)iM of doxorubicin. 
2.2. METHODS 
2.2.1. In vitro studies 
2.2.1.1. LDL, doxorubicin complex formation 
10 mg of doxorubicin was dissolved with 1ml of autoclaved double 
distilled water. After vigorous vortex, all the powder was dissolved. One ml of LDL, 
which contained 6.2 mg of protein, was mixed with 62|il of doxorubicin solution 
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which contained 0.62mg doxorubicin. The mixture was incubated in shaking air-bath 
at 37°C for 24 hours in dark at 800x g. The mixture was then centriftiged at 800x g 
for 10 minutes and loaded onto gel filtration on G25 Sephadex column, which was 
purchased from Amersham Pharmacia Biotech, using 0.9% saline as running buffer 
to separate the free doxorubicin from Low Density Lipoprotein-Doxorubicin (LDL-
Dox) complex. Fractions were collected. The LDL-Dox complex so obtained was 
sterilized by passage through a 0.45 )im acetate millipore filter, which was purchased 
from Millipore Company. 
2.2.1.2. Determination of the concentration of LDL-Dox 
After doxorubicin is coupled into LDL, it is not accurate if its 
concentration is determined only by reading absorbance at wavelength 480nm 
because it is encapsulated in the LDL. So releasing doxorubicin from LDL is 
important for measuring its concentration in the complex. Acidified isopropanol was 
used in this aspect. Dox in LDL-Dox complex was extracted by adding 780|al of 
acidified isopropanol into 20)il of the complex. A standard curve of the concentration 
of doxorubicin in acidified isopropanol versus the absorbance at wavelenght 480nm 
was obtained. The concentration of LDL-Dox was determined by using this standard 
curve. 
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2.2.1.3. In vitro cytotoxicity 
The relationship between cells and drug sensitivity could be 
determined by MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) 
assay. Firstly, cells at 2 x lO"^  cells/well, 1 x lO'^cells/well and 5 x 10^  cells/well were 
seeded into 96-well plate overnight for 24 hours, 48 hours and 72 hours respectively. 
Then the medium was replaced with various concentrations of Dox in RPMI 1640 
with 10% FBS or LDL-Dox in RPMI 1640 with 10% lipoprotein deficient serum 
(LPDS). The plate was then incubated at 37�C，5% CO2 for different time courses 
treatment. 
After the treatment, the medium in each well was removed and the 
cells were washed twice with PBS. Then 30ul of 5mg/ml MTT solution was added to 
each well for 2 hours at 37°C, 5% CO2. After that, the MTT solution was discarded 
and lOOul of DMSO was added to each well in order to dissolve the crystal formed 
by the cells. These plates were incubated for 15 min at 37�C，5% CO2. Finally, the 
plates were measured by ELISA microplate reader (BIO-RAD) at wavelength 
540nm. 
The results were presented as mean of percentage of survival 士 S.D. 
for the indicated number of different experiments. The percentage of survival cells 
was calculated by dividing the difference of the absorbance of treated cells and the 
absorbance of untreated cell multiplied by 100. 
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2.2.1.4. The cytotoxicity of the combined treatment with anticancer 
drugs 
2.2.1.4.1. Combined treatment of hyperthermia with anticancer drugs 
The relationship between cells and combined treatment of drug and 
hyperthermia could be determined by MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay. Firstly, cells at 1 x cells/well were seeded 
into the 96-well plate overnight, then different concentrations of Dox in RPMI 1640 
with 10% FBS or LDL-Dox in RPMI 1640 with 10% lipoprotein deficient serum 
(LPDS) were added as well as incubated at 43°C for 4 hours at different time 
interval. 
For the 48 hours drug treatment, one of the approaches was that after 
adding the drugs, the cells were incubated at 43�C for 4 hours immediately. Then the 
cells were changed back to incubate at 37°C for the rest of 44 hours after adding 
drugs. 
Another approach was that, the cells were incubated for 22 hours after 
adding the drug, then the incubation temperature was changed from 37�C to 43�C and 
the incubation will be continued for 4 hours. Then cells were changed back to 
incubate at 37°C until 48 hours after adding the drugs. 
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After the treatment, the medium in each well was removed and the 
cells were washed twice with PBS. Then 30ul of 5mg/ml MTT solution was added to 
each well for 2 hours at ZTC, 5% CO2. After that, the MTT solution was discarded 
and lOOul of DMSO was added to each well in order to dissolve the crystal formed 
by the cells. These plates were incubated for 15 min at 37�C，5% CO2. Finally, the 
plates were measured by ELISA microplate reader (BIO-RAD) at wavelength 
540nm. 
The results were presented as mean of percentage of survival 土 S.D. 
for the indicated number of different experiments. The percentage of survival cells 
was calculated by dividing the difference of the absorbance of treated cells and the 
absorbance of untreated cell multiplied by 100. 
2.2.1.4.2.Combined treatment of Fructus Crataegus (FC) with LDL-Dox 
The relationship between cells and comined treatment of Fructus 
Crataegus (FC) with LDL-Dox could be determined by MTT (3-[4,5-
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Firstly, cells at 5 x 
103 cells/well were seeded into the 96-well plate overnight, then the medium was 
replaced with Img/ml of FC in RPMI 1640 with 10% lipoprotein deficient serum 
(LPDS). The plate was then incubated at 37°C, 5% CO2 for 48 hours. After 48 hours 
pre-treatment, the medium was discarded and different concentrations of LDL-Dox 
in RPMI 1640 with 10% LPDS were added and incubated at 37°C, 5% CO2 for 
further 24 hours. 
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After the treatment, the medium in each well was removed and the 
cells were washed twice with PBS. Then 30ul of 5mg/ml MTT solution was added to 
each well for 2 hours at 37°C, 5% CO2. After that, the MTT solution was discarded 
and lOOul of DMSO was added to each well in order to dissolve the crystal formed 
by the cells. These plates were incubated for 15 min at 37°C, 5% CO2. Finally, the 
plates were measured by ELISA microplate reader (BIO-RAD) at wavelength 
540nm. 
The results were presented as mean of percentage of survival 土 S.D. 
for the indicated number of different experiments. The percentage of survival cells 
was calculated by dividing the difference of the absorbance of treated cells and the 
absorbance of untreated cell multiplied by 100. 
2.2.1.5. The preparation of Fructus Crataegus (FC) 
The Fructus Crataegus extract was passed through Ssyio cartridge 
dialysis tube whose cut off size was 3000 Dalton. Then the extract would be divided 
into three parts, the first part was retainable part. This part would be lyophilized and 
got a powder call "Say 10 Powder". The second part was the permeated powder which 
would be discarded. The last part was the crude extract which was used for this 
investigation. Firstly, O.IN NaOH was used to wash the cartridge materials at pH 13. 
Then the supernatant was adjust at pH 1.38 followed by centrifuged at 2200x g for 
30 min. After that the supernatant was removed, the participate was redissolved by 
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double distilled water. Then the solution would be lyophilized to get a powder called 
"O.IN NaOH wash materials". 
2.2.1.6. Western blot 
The expression level of LDL-R and P-glycoprotein were investigated. 
Cell at 1 X 10^ cells/well were seeded in 6-well plate overnight. Then the cells were 
incubated with different conditions: complete RPMI 1640 medium (CTL), RPMI 
1640 medium in 10% lipoprotein deficient serum (LPDS), 1 mg/ml FC in 10% LPDS 
RPMI 1640 medium, Img/ml FC and 0.2mg/ml LDL in 10% LPDS RPMI 1640 
medium, and 0.2mg/ml LDL in 10% LPDS RPMI medium for 48 hours incubation. 
After treatment, the medium was removed and the cells were washed twice with IX 
PBS and then incubated with trypsin-EDTA. Then the cells were transferred to 1.5ml 
microfuge tubes followed by centrifuged at 800x g for 5 min. The supernatant was 
then removed and the cells were washed twice with IX PBS. The cells were lysed 
with lOOfil lysis buffer which contained 2% SDS, 10% glycerol, 0.0625M Tris-HCl 
pH 6.8, P-mercaptoethanol (5%v/v), 0.002% bromophenol blue and incubate in ice 
bath for 30 min. After that, the protein samples were boiled in water bath for 15 min 
and the samples were stored at -20�C until the time of analysis. 
The protein sample was quantified by BCA protein assay. The 
working BCA protein assay reagent was prepared by combining reagent A and 
reagent B in the ratio of 50:1. (Reagent A was purchased from Sigma Chemical 
Company and reagent B was prepared as 4% CuS04*5H20). One |il of the samples 
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mixed up with 19|li1 of PBS were added to each well of 96-well plate then followed 
by adding 0.2ml working BCA protein assay reagent. After the plate was incubated 
at 37°C for 30 min, the absorbance was measured by microplate reader at wavelength 
540nm. The concentration of protein could be calculated from the standard curve 
which was plotted by the absorbance at 540nm against protein content of 0，0.5，1.0, 
2.0, 4.0, 6.0，8.0 and 10.0|ag respectively. 
For the Western blot analysis, electrophoresis was performed 
according to the procedure of Laemmil and Favre (1973) with a Mini-Protean set II 
apparatus (Bio-Rad), using a 8% resolving gel and a 4.5% stacking gel. Twenty-five 
|ig samples were diluted with the sample loading buffer (10% glycerol, 0.4% SDS， 
0.05% bromophenol blue and 20mM EDTA in 0.5M Tris-Cl, pH7.5) followed by the 
addition of p-mercaptoethanol (5%v/v). The samples were boiled in a water bath for 
15 min before loading. Electrophoresis was performed at a constant current of 20mA 
at room temperature for each gel. After the tracking dye, bromophenol blue, reached 
the bottom of the gel, electrophoresis was stopped. 
Then the gel was transferred to Immobilon-P membrane (Purchased 
from Millipore Company), treated with 100% methanol and electroblot transfer 
buffer for 5 min, by semi-dry blotter for 60min at 15mA. After the membranes were 
incubated in 10% non-fat dry milk at 4°C overnight, they were rinsed three times 
with TBS-T (IX TBS and 0.1% Tween 20) and rotated for 15 min for three times. 
Then the membranes were incubated with primary antibody (P-glycoprotein or LDL-
R) for 1 hour at room temperature and followed by the secondary antibody (horse-
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radish peroxidase linked anti-rabbit antibody for P-glycoprotein and horse-radish 
peroxidase linked anti-mouse antibody for LDL-R) for 1 hour at room temperature. 
Finally, all proteins bound to primary antibodies followed by secondary antibodies 
were detected by ECL Western blotting detection reagents, which were purchased 
from Amersham Pharmacia Biotech. 
2.2.1.7. Flow cytometry 
Introduction 
Flow cytometry (FCM) has been used extensively to analyze various 
biological properties of cells. Flow cytometry was a measurement of cells in a flow 
system that has been designed to deliver particles in single file past a point of 
measurement. A basic flow cytometry consists of a source of light such as laser 
beam, a low cell, optical components to focus light of different colors on to the 
detectors, electronics to amplify and process the resulting signals and a computer 
(Fig. 2.1). The flow cell is to deliver cells singly to a specific point by hydrodynamic 
focusing at which the source of light is focused. This is achieved by injection of the 
sample into the center of a stream of liquid called the sheath fluid. Light source 
strikes on the cells and the emission of light is collected by detectors. Image analysis 
by computer was then made to study the distribution of light signals emitting from a 
population of cells. 
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Fig. 2.1. Principle of flow cytometry (Becton Dickinson, FacSort model). 
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2.2.1.7.1. Procedures for detecting doxorubicin (Dox) and low density 
lipoprotein-doxorubicin (LDL-Dox) uptake by FCM 
Cells at 1 X 10^ cells/well were seeded in a 6-well plate and incubated 
at 370c, 5% CO2 overnight. The cells were washed by IX PBS. Then the cells were 
incubated with different conditions: complete RPMI 1640 medium (CTL), RPMI 
1640 medium in 10% lipoprotein deficient serum (LPDS), Img/ml FC in 10% LPDS 
RPMI 1640 medium, Img/ml FC and 0.2mg/ml LDL in 10% LPDS RPMI 1640 
medium, and 0.2mg/ml LDL in 10% LPDS RPMI medium for 48 hours incubation. 
After that, the medium was removed and washed twice by IX PBS. 
Then 2ml of \\xM of LDL-Dox in LPDS medium or l^iM of Dox in complete 
medium was added in the cells for 1 hour incubated at 37°C or 43�C. After the 
incubation, the treated cells were washed twice with IX PBS. The adhered cells were 
trypsinised and centrifuged at about 300x g for 3 minutes. The supernatant was 
removed and the pellet was then resuspend by RPMI 1640 without phenol red. 
Finally, the cells were transferred to the flow cytometric tubes. Cells were acquired 
on the system of FACsort flow cytometer (Becton Dickinson). The acquisition of 
cells was analysed by Lysys II program (Becton Dickinson). An excitation filter with 
488nm wavelength (Argon laser) was selected. The population of cells was 
determined by forward scatter (FSC) light and side scatter (SSC) light. FSC and SSC 
determined the size and the granularity of a cell respectively. The signal of 
doxorubicin was collected at channel FL-2 height (red fluorescence). For the flow 
cytometric analysis, the fluorescence properties of about 1 x.lO* cells were collected. 
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2.2.1.8. Confocal laser scanning microscopy 
Introduction 
Confocal laser scaning microscopy (CLSM) allows 3-D 
measurements of biological structures with high spatial contrast. CLSM achieves 
high resolution of a selected plane in a specimen by means of three basic steps. Light 
is focused by an objective lens into an hourglass-shaped beam so that the beam 
strikes one spot at some chosen depth in a specimen (Fig. 2.2). Light reflected from 
that spot is focused to a front of a detecting device such as photomultiplilier tube 
(PMT). Meanwhile the opaque regions around the pinhole block out most of the rays 
that would tend to obscure the resulting image, those reflected by illuminated parts of 
the specimen lying above and below the plane of interest. Finally, the light is moved 
rapidly from point to point in the specimen until the entire plane has been scanned. 
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Fig. 2.2. Principle of Confocal laser scaning microscopy. 
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2.2.1.8.1. Procedures for detecting the cellular of doxorubicin and LDL-DOX 
Cells at 1 X 104 cells/ml and 2 x cells/ml in 1.5ml were seeded on 
a round cover glass with complete RPMI 1640 medium overnight for HepG2 cells 
and R-HepG2 cells respectively. The cells were washed twice by IX PBS. Then the 
cells were incubated with different conditions: complete RPMI 1640 medium (CTL), 
RPMI 1640 medium in 10% lipoprotein deficient serum (LPDS), 1 mg/ml FC in 10% 
LPDS RPMI 1640 medium, Img/ml FC and 0.2mg/ml LDL in 10% LPDS RPMI 
1640 medium，and 0.2mg/ml LDL in 10% LPDS RPMI medium for 48 hours 
incubation. 
After that, the medium was removed and washed by IX PBS. Then 
1.5ml of 5|LIM of LDL-Dox in LPDS medium or 5fiM of Dox in complete medium 
was added into cells for 1 hour incubation at 37�C or 43°C. After the incubation, the 
treated cells were washed with RPMI 1640 medium without phenol red twice. 
The cover glasses were mounted on a homemade holder followed by 
adding 0.5ml RPMI 1640 medium without phenol red. The cells were then observed 
under CLSM at room temperature. Images of cells were acquired on Multiprobe 
2001 from Molecular Dynamics that fitted with an argon laser 6 mW at excitation 
and Nikon diaphot inverted microscope. An excitation filter with 488nm wavelength 
and a long-pass emission filter of 510 nm were used. Cells were scanned by using a 
60X (Nikon planApo) or lOOX (Nikon, Fluor) oil objectives with low-fluorescence 
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immersion oil (Stephens Scientifies, USA). The voltage of the Photomultiplier Tube 
(PMT) was set at optimum. Images were processed by an image analysis software 
2.2.2. In vivo studies 
2.2.2.1. Subcutaneous injection of R-HepG2 cells in nude mouse 
Suspension of 8 x 10^ of human resistant hepatoma R-HepG2 cells 
were injected subcutaneously (s.c.) into the anterior part of the athymic nude mice. 
2.2.2.2. Treatment schedules 
Treatments were started 2 days after R-HepG2 cells were implanted 
onto the mice. The mice were randomly assigned to therapy and control groups of 5 
mice a group. The free Dox at dose level of Img/kg and 2mg/kg as well as LDL-Dox 
at dose levels of Img/kg were injected into the tail vein on one injection per two days 
schedule. The injections were given for 4 weeks. Tumor volume was monitored by 
Vernier caliper measurements weekly and tumor volumes were calculated according 
to the formula: 
Tumor volume ( M M � ) =1/2L x 1/2W X H X T I 
where n - 3.1416 
L = Length of the tumor 
W = Width of the tumor 
H = Height of the tumor 
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2.2.2.3. Assay of investigating of the myocardial injury 
Myocardial injury was accessed by measuring the extent of lactate 
dehydrogenase (LDH) and creatine kinase (CK) leakage after prolonged treatment of 
drugs on nude mice. Nude mice bearing R-HepG2 cells were anesthetized with 
diethyl ether. A 25G syringe, which was pre-washed with Heparin solution, was 
injected into the heart directly. About 0.8ml per mouse blood was collected in a 
1.5ml microtube. Then it was centrifuged at 15,000x g for 15 minutes to separate the 
red blood cells and plasma. After centrifugation, plasma which at the upper layer was 
pipetted into a new tube. Plasma LDH activity of coronary effluent was assayed by 
adding 50ul of plasma into the mixture of 7mM nicotinamide adenine dinucleotide 
(NADH) and 50mM pyruvate. The reaction mixture in a final volume of 1ml was 
estimated by monitoring spectrophotomertrically at wavelength 340nm at 30°C. 
Plasma CK activity of coronary effluent was assayed by adding 20ul of plasma into 
the mixture of 30mM creatine phosphate, 2mM adenosine diphosphate (ADP), 5mM 
adenosine monophosphate, 5mM nicotinamide adenine dinucleotide (NAD), 20mM 
N-acetyl-L-cysteine, 3000U/L Hexokinase (HK) (yeast), 2000U/L glucose-6-
phosphate dehydrogenase (G-6-PDH) (L.m.)，lOmM magnesium ions, 20mM D-
Glucose，10|LIM di(adenosine 5')pentaphosphate and 2mM EDTA at pH 6.7 ± 0.1. 
The reaction mixture in a final volume of 1ml was estimated by monitoring 
spectrophotomertrically at wavelength 340nm at 30°C. 
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2.2.2.4. Tissue preparation procedure for light microscope (LM) 
The nude mice were sacrificed by cervical dislocation on the day after 
the last injection of the drugs. Hearts were removed immediately with care handling. 
The procedures for tissue preparation for light microscopic study were processed by 
the following: 
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Procedure Reagent Time 
Fixing 10% buffered formalin At least 2 days 
Processing: Dehydration 50% EtOH 1 hour 30 min 
70% EtOH 1 hour 30 min 
85% EtOH 1 hour 30 min 
95% EtOH 2 hours 
Absolute EtOH 45 min 
Absolute EtOH 45 min 
Absolute EtOH 45 min 
Clearing Xylene: EtOH (1:1) 30 min 
Xylene 30 min 
Xylene 45 min 
Infiltration Paraffin wax 1 hour 30 min 
Paraffin wax 1 hour 30 min 
Embedding: Tissues were embedded in paraffin wax 
Sectioning: Tissues were cut into sections of 4 |im in thickness, adhere on slides and 
dry on oven overnight 
Staining: Dewax Xylene 5 min 
Xylene 5 min 
Hydration Absolute EtOH 1 min 
95% EtOH 1 min 
70% EtOH 1 min 
50% EtOH 1 min 
30% EtOH 1 min 
Running tap water 1 min 
Staining Harris hematoxylin 7 min 
Running tap water 1 min 
Acid EtOH ~ 1-5 sec 
Running tap water 1 min 
Scott's tap water 1 min 
Running tap water 1 min 
0.5% aqueous Eosin 1-2 min 
Running tap water 1 min 
Dehydration 70% EtOH 1 min 
95% EtOH 1 min 
Absolute EtOH 2 min 
Absolute EtOH 2 min 
Xylene: EtOH (1:1) 2 min 
Xylene 2 min 
Xylene 2 min 
Mounting: Slides were mounted with Canada Balsam 
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The sections were observed under light microscope (OLYMPUS) by 
different combination of magnification values of the eyepieces and objective lens of 
the microscope. Pictures of the heart sections under microscope were taken for 
record and comparison. 
2.2.3. Statistical analysis in our research 
Statistical analysis was done using the Student's t-test. 
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CHAPTER 3 : RESULTS 
3.1. IN VITRO STUDIES 
3.1.1. The preparation of low density lipoprotein-doxorubicin (LDL-
Dox) 
After LDL was mixed up with Dox in shaking air-bath at 37�C for 24 
hours in dark, the mixture was then centrifuged at 800x g for 3 minutes and loaded 
onto G25 Sephadex column using 0.9% saline as running buffer to separate the free 
Dox from LDL-Dox complex. In each fraction, O.Sml aliquots were collected. 
The collecting fractions were monitored at wavelength 480nm and 
280nm to determine the LDL-Dox concentration. The graph Fig. 3.1 showed that 
there was only one peak at wavelength 280nm which represented the absorbance of 
protein and there were two peaks at wavelength 480nm which represented the 
absorbance of Dox. The peak overlapped at wavelength 280nm and 480nm 
represented the LDL-Dox and the peak only appeared at wavelength 480nm 
represented the free Dox. 
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After using Lowery's method to measure the protein contents in the 
collecting fractions, only fraction 5, 6, and 7 were found to contain protein. These 
fractions were pooled together to measure the concentration of Dox in LDL-Dox 
complex. These pooled fractions were dissolved in acidified isopropanol in order to 
release Dox from LDL. 
According to the pilot studies in our laboratory, it showed that the 
LDL in the pooled fractions did not affect the absorbance of Dox in acidified 
isopropanol. 
The LDL-Dox used in the following investigation was only collected 
from the first few fractions of the mixture (fraction 5, 6’ and 7) to ensure that these 
fractions only contained LDL-Dox, but not the free Dox which appeared from 
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Fig. 3.1. The chromatography of purification of low density lipoprotein-doxorubicin 
(LDL-Dox). The 
mixture of 6.2mg low density lipoprotein (LDL) and 0.62nig 
doxorubicin (Dox) were incubated in 3TC shaking air bath at dark environment for 
24 hours. After incubation, the mixture was centrifuged at 800x g for 3 min in a 
desktop centrifuge. The supernatant was loaded into a 5ml pre-packed G-25 
Sephadex column evenly. After the sample just ran into the column, 0.9% of saline 
was applied as a running buffer. Fractions of 0.5ml were collected in the microtubes. 




3.1.2 Studies on human hepatoma cells line (HepG2 cells) 
3.1.2.1.The comparison of Dox and LDL-Dox accumulated in HepG2 cells 
Since the expression level of low density lipoprotein receptor (LDL-
R) on tumor cells was high, it is interested to test whether the accumulation of Dox in 
LDL-Dox treated cells was higher than that of free Dox treated tumor cells. Fig. 3.2 
shows the comparison of Dox and LDL-Dox accumulated in HepG2 cells. After 
measuring the accumulation of drug in HepG2 cells, it showed that the mean of the 
fluorescent intensity of cells on Dox treatment was 11.76 and the mean of the 
fluorescent intensity of cells on LDL-Dox treatment was 19.46. It indicated that the 
accumulation of Dox in LDL-Dox treated cells was higher than that of free Dox 
treated cells. 
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Fig. 3.2. The quantitative analysis of doxorubicin and low density lipoprotein-
doxorubicin accumulated in HepG2 cells. Cells at 1 x 10^  cells/well were seeded in 
6-well plate for 48 hours. Cells were treated with l^iM Dox in complete medium or 
LDL-Dox in lipoprotein deficient serum for 1 hour. The accumulation of Dox and 
LDL-Dox was measured by flow cytometric analysis. The black line represented the 
control cells, i.e. cells incubated without Dox or LDL-Dox. The red line represented 
the cells incubated with IfxM Dox. The green line represented the cells incubated 
with l^iM LDL-Dox. 
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3.1.2.2. Confocal laser scanning microscopic (CLSM) studies on the 
accumulation of Dox and LDL-Dox in HepG2 cells 
According to the result of flow cytometric analysis, it showed that the 
level of LDL-Dox accumulated in the HepG2 cells was more than that of Dox. Since 
Dox had fluorescent, the comparison of Dox and LDL-Dox accumulated in the cells 
can also be monitored by the confocal laser scanning microscopy (CLSM). The 
higher fluorescent intensity, the more Dox or LDL-Dox was present in the cells. In 
Fig. 3.3，the results of confocal laser scanning microscopic images of Dox-treated 
cells and LDL-Dox-treated cells were shown in pseudo-color. The warm color 
represented a high degree of fluorescence whereas cool color represented a low 
degree of Dox fluorescence. 
From the graph, it found that the cells treated with LDL-Dox showed 
a higher degree of fluorescent intensity than that treated with Dox. This result 
suggested that the intracellular level of LDL-Dox was higher than that of Dox which 
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Fig. 3.3. The confocal laser scanning microscopic analysis on the accumulated level 
of Dox and LDL-Dox in HepG2 cells. Cells at 5 x were seeded on cover glass for 
48 hours. The cover glass was incubated with 5fj.M Dox or LDL-Dox at 37°C 5% 
CO2 for 1 hour. (A), Dox-treated HepG2 cells were scanned along the Z-axis for 1 \im. 
(B), LDL-Dox-treated HepG2 cells were scanned along Z-axis for \\im. 
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3.1.2.3.The comparsion of the cytotoxicity of Dox and LDL-Dox on HepG2 cells 
The HepG2 cells were incubated at different concentrations of Dox 
and LDL-Dox ranging from 10|iM to 0.3125|aM under 37°C, 5% CO2 for 24 hours, 
48 hours and 72 hours respectively. The cell viability was determined by MTT assay. 
When the cells were incubated for 24 hours, the I C 5 0 of Dox and 
LDL-Dox were found to be 1.7|LIM and 8.9)^M respectively (Fig. 3.4). In addition, 
when the incubation time was prolonged from 24 hours to 48 hours, the I C 5 0 of Dox 
and LDL-Dox were found to be 0.6|LIM and 4.7|NM respectively (Fig. 3.5). After 72 
hours incubation, the I C 5 0 of Dox and LDL-Dox were found to be 0.3)iM and 3.6[iM 
respectively (Fig. 3.6). 
These results showed that as the concentrations of Dox and LDL-Dox 
was increased, the values of cell viability were decreased, i.e. the percentage of cell 
survival was dose-dependent (Fig. 3.7). When the incubation time was prolonged, the 
values of cell viability were also decreased, i.e. the percentage of cells survival was 
time-dependent (Fig. 3.8). Hence, the percentage survival of HepG2 cells was time-
and dose- dependent on incubation of Dox and LDL-Dox. 
On the other hand, the results also indicated that after Dox coupling 
into the LDL, its cytotoxic effect on HepG2 cells was decreased. This result implied 
it might need a longer time for Dox to release from LDL-complex. 
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The cytotoxicity of HepG2 cells on Dox and LDL-Dox 
after 24 hours treatment 
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Fig. 3.4. Effect of doxorubicin and low density lipoprotein-doxorubicin on the 
survival of HepG2 cells after 24 hours incubation. Cells at 2 x cells/well were 
seeded in a 96 wells plate overnight. Cells were treated with different concentrations 
of Dox and LDL-Dox for 24 hours. The percentage of cell survival was analyzed by 
MTT assay. In each well, 30|il MTT solution and 100|il DMSO were added and the 
absorbance of the mixture was measured at wavelength 540nm. The % survival of 
each incubation was calculated as described in Material & Methods. 
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The cytotoxicity of HepG2 cells on Dox and LDL-Dox 
after 48 hours treatment 
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i ^ 40- \ ^ ^ ^ ^ ^ ^ ^ 
0 1 1 1 I i 
0 2 4 6 8 10 12 
- 20 -I 
Dox _ ) 
Sample The value oflCso 
D ^ 0 6 
LDL-Dox 4/7 
Fig. 3.5. Effect of doxorubicin and low density lipoprotein-doxorubicin on the 
survival of HepG2 cells after 48 hours incubation. Cells at 1 x cells/well were 
seeded in a 96 wells plate overnight. Cells were treated with different concentrations 
of Dox and LDL-Dox for 48 hours. The percentage of cell survival was analyzed by 
MTT assay. In each well, 30|il MTT solution and lOO i^l DMSO were added and the 
absorbance of the mixture was measured at wavelength 540nm. The % survival of 
each incubation was calculated as described in Material & Methods. 
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The cytotoxicity of HepG2 cells on Dox and LDL-Dox 
after 72 hours treatment 
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Fig. 3.6. Effect of doxorubicin and low density lipoprotein- doxorubicin on the 
survival of HepG2 cells after 72 hours incubation. Cells at 3 x 10^ cells/well were 
seeded in a 96 wells plate overnight. Cells were treated with different concentrations 
of Dox and LDL-Dox for 72 hours. The percentage of cell survival was analyzed by 
M T T assay. In each well, 30|li1 M T T solution and lOOjil D M S O were added and the 
absorbance of the mixture was measured at wavelength 540nm. The % survival of 
each incubation was calculated as described in Material & Methods. 
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The cytotoxicity of HepG2 cells on Dox at different time 
course treatments 
— 2 4 hours tretment 
100 ji —•— 48 hours treatment 
\ 72 hours treatment 
80 - 5 
K t—« 60 “ ^^  ^^  ———- — 
0 ^ ^ I . , ~ ： i 
<» 2 4 6 8 10 12 
-20 J 
Dox (pM) 
Time course The value of I C 5 0 on Dox 
24 hours I J ‘ 
48 hours 0 6 “ 
72 hours o J " 
Fig. 3.7. Effect of doxorubicin on the survival ofHepG2 cells at different time course 
treatments. Cells at 2 x ⑴斗，1 x 104 and 3 x lO，cells/well were seeded in a 96 wells 
plate overnight. Cells were treated with different concentrations of doxorubicin for 
24，48 and 72 hours respectively. The percentage of cell survival was analyzed by 
MTT assay. In each well, 30|il MTT solution and lOO i^l DMSO were added and the 
absorbance of the mixture was measured at wavelength 540nm. The % survival of 
each incubation was calculated as described in Material & Methods. 
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The Cytotoxicity of HepG2 cells on LDL-Dox after 
different time course treatments 
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100 • 48 hours treatment 
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Fig. 3.8. Effect of low density lipoprotein-doxorubicin on the survival of HepG2 
cells at different time course treatments. Cells at 2 x 10^ 1 x and 3 x 10^  
cells/well were seeded in a 96 wells plate overnight. Cells were treated with different 
concentrations of LDL-Dox for 24, 48 and 72 hours respectively. The percentage of 
cell survival was analyzed by MTT assay. In each well, 30|^1 MTT solution and 
lOOjLil DMSO were added and the absorbance of the mixture was measured at 
wavelength 540nm. The % survival of each incubation was calculated as described in 
Material & Methods. 
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3.1.2.4.The comparison of the cytotoxicty of Dox and LDL-Dox with and 
without hyperthermia on HepG2 cells 
When the HepG2 cells were incubated at 43°C at different time 
periods, the cytotoxic effect of Dox and LDL-Dox were higher than those obtained at 
37°C. HepG2 cells were incubated at 43°C for 4 hours at two different periods, 
namely hyperthermia was applied at the beginning of drugs treatment, i.e. at 0 hour 
to 4 hours during the treatment and hyperthermia was applied in the middle of the 
drug treatment, i.e. at 22 hours to 26 hours during the treatment. For the Dox 
treatment, the cytotoxicity of Dox under hyperthermia was higher than that without 
hyperthermia. Moreover, the effect of hyperthermia applied at the beginning or in the 
middle of the drug treatment was similar (Fig. 3.9). 
For LDL-Dox treatment, when the cells were incubated at 43�C，the 
cytotoxic effect of LDL-Dox either adding LDL-Dox immediately or in the middle 
of the treatment was also increased when compared with those obtained by LDL-Dox 
treatments only. That means the cytotoxicity of LDL-Dox combined with 
hyperthermia was higher than that without hyperthermia (Fig. 3.10). The 
hyperthermia effect occurred after adding drug immediately was similar to that 
occurred in the middle of drug treatment. 
According to the above results, it suggested that the hyperthermia 
could enhance the cytotoxic effect of Dox and LDL-Dox on HepG2 cells. 
Furthermore, the hyperthemia effect did not have a significant difference on the Dox 
- 7 3 -
RESULTS 
and LDL-Dox treatments no matter whether hyperthermia was applied at the 
beginning or in the middle of the drug treatment. 
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The cytotoxicityof combined treatment with Dox 
and hyperthermia on HepG2 
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Fig. 3.9. Effect of combined treatment with doxorubicin and hyperthermia on the 
survival of HepG2 cells. Cells at 1 x cells/well were seeded in a 96 wells plate 
overnight. Cells were treated with different concentrations of Dox for 48 hours. 
During the incubation time, the hyperthermia treatment was applied immediately 
after adding drugs or in the middle of the drug treatment. The percentage of cell 
survival was analyzed by MTT assay. In each well, 30}al MTT solution and 100… 
DMSO were added and the absorbance of the mixture was measured at wavelength 
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The cytotoxicity of combined treatment with LDL-Dox and 
hyperthermia on HepG2 cells 
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Fig. 3.10. Effect of combined treatment with low density lipoprotein-doxorubicin and 
hyperthermia on the survival of HepG2 cells. Cells at 1 x 10^ cells/well were seeded 
in a 96 wells plate overnight. Cells were treated with different concentrations of 
LDL-Dox for 48 hours. During the incubation time, the hyperthermia was applied 
immediately after adding drugs or in the middle of the drug treatment. The 
percentage of cell survival was analyzed by MTT assay. In each well, 30|il MTT 
solution and 100|li1 DMSO were added and the absorbance of the mixture was 
measured at wavelength 540nm. The % survival of each incubation was calculated as 
described in Material & Methods. 
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3.1.2.5.The comparison of accumulation of Dox and LDL-Dox in HepG2 cells 
treated with and without combination of hyperthermia 
The results of Dox and LDL-Dox combined with hyperthermia 
indicated that hyperthermia could enhance the cytotoxic effect of Dox and LDL-Dox. 
Whether this effect was enhanced by the accumulation of Dox and LDL-Dox in the 
cells were examined by flow cytometric analysis. 
When comparing between the accumulations of l |iM of Dox in the 
HepG2 cells incubated at 37�C and 4 3 � C both at 5% CO2 1 hour, the mean of the 
fluorescent intensity of cells incubated at 37°C was 15.12 and the mean of the cells 
incubated at 43°C was 21.88. There was an increase in the accumulation of Dox into 
the cells incubated at 43°C when compared with those incubated at 37°C, which 
implied that increased intracellular accumulation of Dox from 37°C to 43°C could be 
observed (Fig. 3.11). 
In addition, when comparing between the accumulation of \\xM of 
LDL-Dox in the HepG2 cells incubated at 37°C and 4 3 � C both at 5%C02 for 1 hour, 
the mean of the fluorescent intensity of cells incubated at 3 7 � C and 4 3 � C was both 
30.23. There was no clear difference between the accumulation of LDL-Dox in the 
cells under hyperthermia or not (Fig. 3.12). 
These results showed that hyperthermia could enhance the 
accumulation of Dox in�the cells, but not for LDL-Dox. 






Sample Mean Fluorescence Value / units 
Control at 37°C ^ 
Dox at 37�C 15.12 
Dox at 43�C 21.88 
Fig. 3.11. The quantitative analysis of doxorubicin accumulated in HepG2 cells. 
Cells at 1 X 10^  cells/well were seeded in 6-well plate for 48 hours. Cells were treated 
with l)aM Dox for 1 hour at 37°C or 43°C. The accumulation of Dox was measured 
by flow cytometric analysis. The black line represented the control cells, i.e. cells 
incubated without Dox at 37°C. The red line represented the cells incubated with 
l^M Dox at 37°C. The green line represented the ceils incubated with 1|LIM LDL-
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Sample Mean Fluorescence Value / units 
Control at 37�C ^ 
LDL-Dox at 37�C 30.23 
LDL-Dox at 43°C 30.23 
Fig. 3.12. The quantitative analysis of low density lipoprotein-doxorubicin 
accumulated in HepG2 cells. Cells at 1 x 10^  cells/well were seeded in 6-well plate 
for 48 hours. Cells were treated with 1 juM LDL-Dox for 1 hour at 37�C or 43°C. The 
accumulation of LDL-Dox was measured by flow cytometric analysis. The black line 
represented the control cells, i.e. cells incubated without LDL-Dox at 37°C. The red 
line represented the cells incubated with 1|4,M LDL-Dox at 37°C. The green line 
represented the cells incubated with 1 |liM LDL-DOX at 43°C. 
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3.1.2.6.Confocal laser scanning microscopic (CLSM) studies on the 
accumulation of Dox and LDL-Dox in HepG2 treated cells with and 
without hyperthermia 
The result of flow cytometric analysis showed that after the cells 
incubated at 43 °C with Dox, the accumulation level of Dox in the cells was higher 
than that of the cells incubated at 37�C with Dox. From the confocal laser scanning 
microscopic images of Dox-treated cells at 37°C and 43°C，it showed that those 
observed in 43°C-treated cells showed a higher fluorescent intensity when compared 
with those observed in 37°C-treated cells. This result suggested that the intracellular 
level of Dox was enhanced by hyperthermia (Fig. 3.13). 
In addition, when comparing the level of LDL-Dox accumulated in 
the cells incubated between at 37�C and 43�C，the fluorescent intensity of LDL-Dox 
in cells incubated at 37°C was similar to that observed in cells incubated at 43°C, 
indicating that there was no clear difference between the effect in cells treated with 
hyperthermia or not (Fig. 3.14). 
These results suggested that the combined treatment of Dox and 
hyperthermia could enhance the intracellular level of Dox, but hyperthermia could 
not enhance the intracellular level of LDL-Dox. These results were comparable to 
those of flow cytometric analyses. 
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Fig. 3.13. The confocal laser scanning microscopic analysis on the accumulated level 
of Dox in HepG2 cells. Cells at 5 x cells were seeded on cover glass for 48 hours. 
The cover glass was incubated with S i^M Dox for 1 hour at 37°C or 43°C. (A), Dox-
treated HepG2 cells incubated at 37�C were scanned along the Z-axis for l^m. (B), 
Dox-treated HepG2 cells incubated at 43°C were scanned along Z-axis for l^im. 
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Fig. 3.14. The confocal laser scanning microscopic analysis on the accumulated level of LDL-Dox 
in HepG2 cells. Cells at 5 x 10^  cells were seeded on cover glass for 48 
hours. The cover glass was incubated with LDL-Dox for 1 hour at 37°C or 
43°C. (A), LDL-Dox-treated HepG2 cells incubated at 37�C were scanned along the 
Z-axis for l|Lim. (B), LDL-Dox-treated HepG2 cells incubated at 43°C were scanned 
along Z-axis for l|j,m. 
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3.1.2.7.Modulation of LDL receptors on HepG2 cells Up-
regulation of LDL receptors by Fructus Crataegus (FC) 
3.1.2.7.1.The comparsion of LDL receptor expression on HepG2 cells after 
Fructus Crataegus (FC) pre-treatment 
Results in Fig. 3.15 demonstrated that in HepG2 cells, the LDL 
receptor expression levels in various treatments were different. The cells treated 
with lipoprotein deficient serum (LPDS) showed a little bit higher LDL receptor 
expression than that with complete medium (control). Moreover, the cells treated 
with low density lipoprotein (LDL) only exhibited less LDL receptor expression 
when compared with those treated with LPDS. That means LDL could suppress the 
LDL receptor expression. After the cells were treated with Fructus Crataegus (FC) 
only，the expression level of LDL receptor was higher than the cells treated with 
LPDS，i.e. the FC might up-regulate LDL receptor expression. When the cells were 
co-treated with FC and LDL, the expression level was reduced when compared with 
that in FC-treated cells, but it was still higher than that in cells treated with LDL 
only. These results indicated that the expression level of LDL receptor increased by 
the effect of FC was higher than that suppressed by the effect of LDL. 
The result suggested that FC could up-regulate the expression level of 
LDL receptors and LDL could suppress the expression of LDL receptors on HepG2 
cells. 
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2: FC (Img/ml) in LPDS 
3: FC (Img/ml) and LDL (0.2mg/ml) in LPDS 
4: LDL (0.2mg/ml) in LPDS 
5: Lipoprotein deficient serum (LPDS) 
Fig. 3.15. The expression level of LDL receptors in various treatments in HepG2 
cells. Cells at 1 x 10^ cells/well were seeded in 6 well-plate overnight. Cells were 
treated with complete medium (CTL), lipoprotein deficient serum (LPDS), Fructus 
Crataegus (FC) in lipoprotein deficient serum, co-treatment of Fructus Crataegus 
and low density lipoprotein (FC and LDL) in lipoprotein deficient serum, and low 
density lipoprotein (LDL) in lipoprotein deficient serum. The level of LDL receptor 
was analyzed by Western blot analysis. Aliquots of 25\xg of protein was loaded in 
each lane. 
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3.1.2.7.2.The comparison of accumulation of LDL-Dox accumulated in HepG2 
cells pre-treated with and without Fructus Crataegus (FC) 
As observed in Fig. 3.16, the accumulation of LDL-Dox in HepG2 
cells treated with lipoprotein deficient serum (LPDS) was higher than that when cells 
were treated with complete medium (control). The mean of the fluorescent intensity 
of cells was 17.78 and 14.33 respectively, i.e. an increase LDL-Dox accumulation 
was observed as the cells were treated with LPDS. After the cells were treated with 
LDL, the accumulation of LDL-Dox in the cells was less than that in cells treated 
with LPDS. The results suggest that most of the LDL-receptors might be bound by 
LDL or the expression level of LDL receptors was reduced in order to decrease the 
possibility of LDL-Dox bound to the receptor, thus there was a decreased of LDL-
Dox accumulated in the cells treated with LDL when compared with those in the 
cells treated with LPDS. Moreover, the accumulation of LDL-Dox was increased in 
FC-treated cells when compared with that in cells treated with LPDS. The mean of 
the fluorescent intensity of cells under FC-treatment was 55.23 in which there was an 
increase of the LDL-Dox accumulation was observed when compared with that in 
cells treated with LPDS, i.e. the FC might up-regulate LDL receptors on the cells in 
order to increase the LDL-Dox accumulation. Moreover, the increase of fluorescent 
intensity in FC-treated cells did not due to the FC itself, mostly due to the fluorescent 
of Dox. As the cells were co-treated with FC and LDL, the accumulation of Dox in 
LDL-Dox treated cells was lower than that of the cells under FC-treatment only, but 
still higher than that when the cells were treated with LDL only. That means a part of 
LDL receptors up-regulated by FC might be bound by LDL, so the probability of 
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LDL-Dox bound to LDL receptors would be reduced. This phenomenon was 
comparable to the LDL receptor expression level under different kinds of the 
treatments. 
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Control + LDL-Dox 14.33 
LPDS + LDL-Dox 17.78 
LDL + LDL-Dox 15.54 
FC + LDL-Dox 55.23 
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Fig. 3.16. The quantitative analysis of LDL-Dox accumulated in HepG2 cells. Cells 
at 1 X 10^  cells/well were seeded in 6-well plate overnight. Cells were treated with 
complete medium (control), lipoprotein deficient serum (LPDS), low density 
lipoprotein (LDL) in lipoprotein deficient serum, Fructus Crataegus (FC) in 
lipoprotein deficient serum and co-treatment of Fructus Crataegus and low density 
lipoprotein (FC and LDL) in lipoprotein deficient serum for 48 hours. After the pre-
treatment, l|iM LDL-Dox mixing in lipoprotein deficient serum was added for 1 
hour incubation. The accumulation of LDL-Dox was measured by flow cytometric 
analysis. The black line represented the control cells, i.e. cells without incubating 
with LDL-Dox. The red line represented the cells incubated with complete medium 
and l|xM LDL-Dox. The green line represented the cells incubated with lipoprotein 
deficient serum ( L P D S ) and 1|LIM LDL-DOX. The blue line represented the cells 
incubated with low density lipoprotein (LDL) and l^M LDL-Dox. The purple line 
represented the cells incubated with Fructus Crataegus (FC) and l|iM LDL-Dox. 
The brown line represented the cells incubated with of Fructus Crataegus and low 
density lipoprotein (FC and L D L ) and 1 |LIM LDL-DOX. 
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3.1.2.7.3.Confocal laser scanning microscopic (CLSM) studies on the 
accumulation of LDL-Dox in HepG2 cells after Fructus Crataegus (FC) 
pre-treatment 
As observed in Fig. 3.17 & 3.18，in HepG2 cells, the confocal laser 
scanning microscopic images of LPDS-treated cells and complete medium-treated 
cells showed that the LPDS-treated cells showed a higher fluorescent intensity than 
those obtained in the complete medium-treated cells. This result suggested that the 
intracellular level of LDL-Dox under LPDS treatment was higher than that under 
complete medium treatment. After the cells were treated with LDL, the fluorescent 
intensity of cells was lower than that treated with LPDS. It means the LDL could 
suppress LDL receptors expression or most of the LDL receptors was bound by LDL 
in order to decrease the intracellular level of LDL-Dox. When the cells were treated 
with FC, the fluorescent intensity of cells was higher than that of the cells treated 
with LPDS, i.e. the intracellular of LDL-Dox increased was due to the up-regulation 
of LDL receptors expression by FC and most of the fluorescent intensity of cells was 
due to the Dox, not due to the FC itself. But while the cells were co-treated with FC 
and LDL, the fluorescent intensity of cells was lower than that of the cells treated 
with FC-treated only, but still higher than that of the cells treated with LDL only. 
That means the power of up-regulation of LDL receptors by FC was higher than that 
of the level suppessed by LDL on the cells. Thus, the intracellular concentration of 
LDL-Dox under the co-treatment was higher than that of the cells treated with LDL. 
This phenomenon was comparable to the LDL-Dox accumulation in the cells under 
different kinds of treatments. 
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Fig. 3.17. The confocal laser scanning microscopic analysis on the accumulated level 
of LDL-Dox in HepG2 cells. Cells at 5 x cells were seeded on cover glass for 48 
hours. The cover glass was incubated with 5)iM LDL-Dox for 1 hour at 37°C. (A), 
complete medium (control)-treated HepG2 cells were scanned along the Z-axis for 
l|Lim. (B), lipoprotein deficient serum (LPDS)-treated HepG2 cells were scanned 
along Z-axis for l|j.m. (C), Fructus Crataegus (FC) in LPDS-treated HepG2 cells 
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Fig. 3.18. The confocal laser scanning microscopic analysis on the accumulated level 
of LDL-Dox in HepG2 cells. Cells at 5 x 10"* cells were seeded on cover glass for 48 
hours. The cover glass was incubated with 5)j.M LDL-Dox in LPDS for 1 hour at 
37�C. (A), co-treaed with Fructus Crataegus and low density liporotein (FC and 
LDL) in LPDS on HepG2 cells were scanned along the Z-axis for 1 pm. (B), low 
density lipoprotein in LPDS-treated HepG2 cells were scanned along Z-axis for 1 ^m. 
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3.1.2.7.4.Cytotoxicity of combined treatment with LDL-Dox and Fructus 
Crataegus (FC) 
Since the results of the protein expression level of LDL receptors and 
the accumulation of LDL-Dox in the HepG2 cells was increased under FC-treatment, 
the percentage of cell survival under the combined treatment of FC and LDL-Dox 
might be different from the cells treated with LDL-Dox only. 
The HepG2 cells were pre-treated with FC in LPDS medium up to 48 
hours, then the cells were incubated at different concentrations of LDL-Dox ranging 
from 10|iM to 0.3125|aM under 37�C, 5% CO2 for 24 hours and the cells viability 
was determined by MTT assay. After the cells pre-treated with FC, the I C 5 0 of LDL-
Dox was 0.6|^M which was about 15-fold lower than that under LDL-Dox treated 
only，the I C 5 0 of LDL-Dox after 24 hours treatment without FC-treated was 8.9|iM 
(Fig. 3.19). Moreover, there was not any cytotoxic effect of Img/ml FC on HepG2 
cells observed in the previous studies, thus the cytotoxicity of HepG2 cells 
determined in this assay was due to the cytotoxic effect of LDL-Dox. 
The results suggested that after FC pre-treatment, the LDL receptor 
expression level was increased, which could enhance the LDL-Dox accumulated in 




The cytotoxicity of combined treatment with FC and LDL-
Dox on HepG2 cells 
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Fig. 3.19. Effect of combined treatment with low density lipoprotein-doxorubicin and 
the pre-treatment of Fructus Crataegus (FC) on the survival of HepG2 cells. Cells at 
5 x 1 0 cells/well were seeded in a 96 wells plate overnight. Cells were treated with 
Img/ml of FC in lipoprotein deficient serum for 48 hours. After 48 hours, the cells 
were washed with IX PBS twice, then the cells were incubated at' different 
concentrations of LDL-Dox for further 24 hours. The percentage of cell survival was 
analyzed by MTT assay. In each well, 30|al MTT solution and 100^1 DMSO were 
added and the absorbance of the mixture was measured at wavelength 540nm. The % 
survival of each incubation was calculated as described in Material & Methods. 
-92 -
— RESULTS 
3.1.3. Studies on multidrug human resistant hepatoma cell line (R-
HepG2 cells) 
3.1.3.1.The overexpression level of P-glycoprotein in a resistant cell line R-
HepG2 
One phenomenon of multidrug resistant cell lines is the over-
expression of P-glycoprotein. In R-HepG2 cells, they also had a higher expression 
level of P-glycoprotein when compared with HepG2 cells (Fig. 3.20). Therefore the 
I C 5 0 of Dox treated on HepG2 cells were usually lower than that treated on R-HepG2 
cells. 
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Fig. 3.20. The expression level of P-glycoprotein in HepG2 cells and R-HepG2 cells. 
Cells at 1 X 10 cells/well were seeded in 6 well-plate for 48 hours. The level of P-
glycoprotein was analyzed by Western blot analysis. Aliquot o f25^g of protein was 
loaded in each lane. 
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3.1.3.2.The comparison of Dox and LDL-Dox accumulated in R-HepG2 cells 
Since the higher expression level of P-glycoprotein in R-HepG2 cells, 
Dox might be easily pumped out from the cells, i.e. the concentration of Dox 
accumulated in the cells might be decreased in order to reduce the cytotxic effect of 
Dox on R-HepG2 cells. This hypothesis was examined in the present experiment. As 
shown in Fig. 3.21, the mean of the fluorescent intensity of R-HepG2 cells with and 
without Dox incubation was 10.46 and 8.98 respectively. There was no clear 
difference between the cells incubated with Dox or not. Moreover, the expression 
level of low density lipoprotein receptor on cancer cells was higher than that of 
normal cells, thus the accumulation of LDL-Dox was higher than that of Dox in R-
HepG2 cells. The mean of the fluorescent intensity of cells on LDL-Dox treatment 
was 25.71. There was an increase of fluorescent intensity of cells treated with LDL-
Dox when compared with the cells treated with Dox. The comparison of Dox and 
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Fig. 3.21. The quantitative analysis of Dox and LDL-Dox accumulated in R-HepG2 
cells. Cells at 1 x 10^  cells/well were seeded in 6-well plate for 48 hours. Cells were 
treated with l|iM Dox in complete medium or LDL-Dox in lipoprotein deficient 
serum for 1 hour. The accumulation of Dox and LDL-Dox was measured by flow 
cytometric analysis. The black line represented the control cells, i.e. cells incubated 
without Dox or LDL-Dox. The red line represented the cells incubated with 1 |liM 
Dox. The green line represented the cells incubated with 1 LDL-Dox. 
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3.1.3.3.Confocal laser scanning microscopic (CLSM) studies on the 
accumulation of Dox and LDL-Dox in R-HepG2 cells 
Since the size of Dox was smaller than the pore size of P-glycoprotein, 
most of the Dox could be pumped out by the P-glycoprotein in R-HepG2 cells. From 
the results of confocal laser scanning microscopic images of Dox-treated cells and 
LDL-Dox-treated cells, it showed that the cells treated with LDL-Dox exhibited a 
higher degree of fluorescent intensity than that with Dox. Moreover, the Dox 
accumulated in the cells was located near the cell membrane (Fig. 3.22). 
This result suggested that the intracellular level of LDL-Dox was 
higher than that of Dox which was comparable to the result of the accumulation of 
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Fig. 3.22. The confocal laser scanning microscopic analysis on the accumulated level 
of Dox and LDL-Dox in R-HepG2 cells. Cells at 5 x cells were seeded on cover 
glass for 48 hours. The cover glass was incubated with 5[iM LDL-Dox for 1 hour at 
37°C, 5% CO2 for 1 hour. (A), Dox-treated R-HepG2 cells were scanned along the Z-
axis for l|Lim. (B), LDL-Dox-treated R-HepG2 cells were scanned along Z-axis for 
l|Lim. 
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3.1.3.4.The comparsion of the cytotoxicity of Dox and LDL-Dox on R-HepG2 
cells 
According to the measurement of Dox accumulated in R-HepG2 cells, 
the P-glycoprotein existing might reduce the concentration of Dox accumulated in 
the cells resulting in a decrease in the cytotoxic effect of Dox. This possibility was 
raised due to the ability to incubate the cells at a higher concentrations of Dox than 
that on HepG2 cells. The concentrations of Dox and LDL-Dox ranging from 400|aM 
to 12.5^M and SO i^M to 1.5626)aM respectively were needed to incubate R-HepG2 
cells under 37°C，5% CO2 for 24 hours, 48 hours and 72 hours. The cells survival 
was determined by MTT assay. 
When the cells were incubated with drugs for 24 hours, the IC50 of 
Dox and LDL-Dox were found to be 368|LIM (Fig. 3.23) and 48|^M (Fig. 3.24) 
respectively. In addition, when the incubation time prolonged from 24 hours to 48 
hours, the IC50 of Dox and LDL-Dox were found to be 300|LIM (Fig. 3.25) and \5\M 
(Fig. 3.26) respectively. After 72 hours incubation, IC50 of Dox and LDL-Dox were 
found to be 240 |AM (Fig. 3.27) and 7|LIM (Fig. 3.28) respectively. 
These results showed that as the concentration of Dox and LDL-Dox 
increased, the numbers of cell viability were decreased, i.e. the percentage of cell 
survival was dose-dependent (Fig. 3.29). Also, when the incubation time was 
prolonged, cell viability was decreased, i.e. the percentage of cells survival was time-
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dependent (Fig. 3.30). Hence, the percentage survival of R-HepG2 cells was time-
and dose- dependent on Dox and LDL-Dox. 
In addition, the I C 5 0 of LDL-Dox was usually lower than that of Dox 
at different time courses. This might indicate that after Dox coupled into LDL, the 
complex was not easily pumped out by the P-glycoprotein in R-HepG2 cells so that 
the cytotoxic effect of LDL-Dox in R-HepG2 cells could be enhanced. 
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The cytotoxicity of R-HepG2 cells on Dox after 24 
hours treatment 
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Fig. 3.23. Effect of doxorubicin on the survival of R-HepG2 cells after 24 hours 
incubation. Cells at 2 x 10^ cells/well were seeded in a 96 wells plate overnight. Cells 
were treated with different concentrations of Dox for 24 hours. The percentage of 
cell survival was analyzed by MTT assay. In each well, 30|al MTT solution and 
100|il DMSO were added and the absorbance of the mixture was measured at 
wavelength 540nm. The % survival of each incubation was calculated as described in 
Material & Methods. 
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The cytotoxicity of R-HepG2 cells on LDL-Dox after 24 
hours treatment 
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Fig. 3.24. Effect of low density lipoprotein-doxorubicin on the survival of R-HepG2 
cells after 24 hours incubation. Cells at 2 x 10^ cells/well were seeded in a 96 wells 
plate overnight. Cells were treated with different concentrations of LDL-Dox for 24 
hours. The percentage of cell survival was analyzed by MTT assay. In each well, 
30|il MTT solution and 100|LI1 DMSO were added and the absorbance of the mixture 
was measured at wavelength 540nm. The % survival of each incubation was 




The cytotoxicity ofR-HepG2 cells on Dox after 48 hours 
treatment 
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Fig. 3.25. Effect of doxorubicin on the survival of R-HepG2 cells after 48 hours 
incubation. Cells at 1 x 10^ cells/well were seeded in a 96 wells plate overnight. Cells 
were treated with different concentrations of Dox for 48 hours. The percentage of 
cell survival was analyzed by MTT assay. In each well, 30|al MTT solution and 
100|al DMSO were added and the absorbance of the mixture was measured at 
wavelength 540nm. The % survival of each incubation was calculated as described in 
Material & Methods. 
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Fig. 3.26. Effect of low density lipoprotein-doxorubicin on the survival of R-HepG2 
cells after 48 hours incubation. Cells at 1 x lO^ cells/well were seeded in a 96 wells 
plate overnight. Cells were treated with different concentrations of LDL-Dox for 48 
hours. The percentage of cell survival was analyzed by MTT assay. In each well, 
30W MTT solution and 100^1 DMSO were added and the absorbance of the mixture 
was measured at wavelength 540nm. The % survival of each incubation was 




The cytotoxicity ofR-HepG2 cells on Dox after 72 hours 
treatment 
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Fig. 3.27. Effect of doxorubicin on the survival of R-HepG2 cells after 72 hours 
incubation. Cells a t3 x 10^ cells/well were seeded in a 96 wells plate overnight. Cells 
were treated with different concentrations of Dox for 72 hours. The percentage of 
cell survival was analyzed by MTT assay. In each well, 30|xl MTT solution and 
lOO i^l DMSO were added and the absorbance of the mixture was measured at 
wavelength 540nm. The % survival of each incubation was calculated as described in 
Material & Methods. 
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Fig. 3.28. Effect of low density lipoprotein-doxorubicin on the survival of R-HepG2 
cells after 72 hours incubation. Cells at 3 x 10^ cells/well were seeded in a 96 wells 
plate overnight. Cells were treated with different concentrations of LDL-Dox for 72 
hours. The percentage of cell survival was analyzed by MTT assay. In each well, 
3(^1 MTT solution and 100|LII DMSO were added and the absorbance of the mixture 
was measured at wavelength 540iim. The % survival of each incubation was 
calculated as described in Material & Methods. 
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The cytotoxicity of R-HepG2 cells on Dox at different 
time course treatments 
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Fig. 3.29. Effect of doxorubicin on the survival of R-HepG2 cells at different time 
course treatments. Cells at 2 x 104，1 x 10^ and 3 x 10^ cells/well were seeded in a 96 
wells plate overnight. Cells were treated with different concentrations of doxorubicin 
for 24, 48 and 72 hours respectively. The percentage of cell survival was analyzed by 
MTT assay. In each well, 30)al MTT solution and lOO i^l DMSO were added and the 
absorbance of the mixture was measured at wavelength 540nm. The % survival of 
each incubation was calculated as described in Material & Methods. 
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The cytotoxicity of R-HepG2 cells on LDL-Dox at 
different time course treatments 
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Fig. 3.30. Effect of low density lipoprotein-doxorubicin on the survival of R-HepG2 
cells at different time course treatments. Cells at 2 x 10^ 1 x and 3 x 10^  
cells/well were seeded in a 96 wells plate overnight. Cells were treated with different 
concentrations of LDL-Dox for 24，48 and 72 hours respectively. The percentage of 
cell survival was analyzed by MTT assay. In each well, 30|al MTT solution and 
lOOW DMSO were added and the absorbance of the mixture was measured at 
wavelength 540nm. The % survival of each incubation was calculated as described in 
Material & Methods. 
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3.1.3.5.The comparison of the cytotoxicty of Dox and LDL-Dox with and 
without hyperthermia on R-HepG2 cells 
In R-HepG2 cells, after the cells were incubated at 43°C at different 
time periods for 4 hours, and the hyperthermia was then applied at the beginning of 
drug treatment, i.e. at 0 hour to 4 hours during the drug treatment, or in the middle of 
the drug treatment, i.e. at 22 hours to 26 hours drug the drug treatment. The cytotoxic 
effect of Dox and LDL-Dox was enhanced by hyperthermia. 
Moreover for the Dox treatment, the IC50 of cells incubated with and 
without hyperthermia at 4 3 � C were 3 0 0 | I M , 180|LIM and 254)IM respectively (Fig. 
3.31). The effect of hyperthermia at the beginning of Dox treatment was higher than 
that in the middle of the drug treatment and their I C 5 0 were 180}iM and 254fiM 
respectively. 
For LDL-Dox treatment, the I C 5 0 of cells incubated with and without 
hyperthermia at 43®C were 15|iM, 62\iM and 8.9|uM respectively (Fig. 3.32). The 
cytotoxic effect of LDL-Dox combined with hyperthermia at the beginning of LDL-
Dox treatment was higher than that in the middle of the drug treatment and their I C 5 0 
were 6.2^M and 8.9|LIM respectively. 
The result suggested that the hyperthermia effect could enhance the 
cytotoxic effect of Dox and LDL-Dox. Furthermore, the effect of hyperthermia 
applied at the beginning of the drug treatment was greater than that observed when 
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htperthermia was applied in the middle of the drug treatment, and this phenomenon 
could be observed at both Dox and LDL-Dox treatment. 
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The cytotoxicty of combined treatment with Dox and 
hyperthermia on R-HepG2 cells 
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Fig. 3.31. Effect of combined treatment with doxorubicin and hyperthermia on the 
survival ofR-HepG2 cells. Cells at 1 x lO"^  cells/well were seeded in a 96 wells plate 
overnight. Cells were treated with different concentrations of Dox for 48 hours. 
During the incubation time, the hyperthermia was applied immediately after adding 
drugs, i.e. at 1 hour to 4 hours of the drug treatment, or in the middle of the drug 
treatment, i.e. at 22 hours to 26 hours of drug treatment. The percentage of cell 
survival was analyzed by MTT assay. In each well, 30)^ 1 MTT solution and 100|al 
DMSO were added and the absorbance of the mixture was measured at wavelength 
540nm. The % survival of each incubation was calculated as described in Material & 
Methods. 
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The cytotoxicity of combined treatment with LDL-Dox 
and hyperthermia on R-HepG2 cells 
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Fig. 3.32. Effect of combined treatment with low density lipoprotein-doxorubicin and 
hyperthermia on the survival of R-HepG2 cells. Cells at 1 x lO"^  cells/well were 
seeded in a 96 wells plate overnight. Cells were treated with different concentrations 
of LDL-Dox for 48 hours. During the incubation time, the hyperthermia was applied 
immediately after adding drugs, i.e. at 1 hour to 4 hours of the drug treatment, or in 
the middle of the drug treatment, i.e. at 22 hours to 26 hours of the drug treament. 
The percentage of cell survival was analyzed by MTT assay. In each well, 30^1 MTT 
solution and 100|LI1 DMSO were added and the absorbance of the mixture was 
measured at wavelength 540nm. The % survival of each incubation was calculated as 
described in Material & Methods. 
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3.1.3.6.The comparison of the accumulation of Dox and LDL-Dox in R-HepG2 
cells treated in combination with hyperthermia 
According to the results of Dox and LDL-Dox combined with 
hyperthermia, hyperthermia could enhance the cytotoxic effect of Dox and LDL-
Dox. Whether this effect was enhanced by the accumulation of Dox and LDL-Dox in 
the cells would be examined by flow cytometric analysis. 
When comparing between the accumulations of l^iM of Dox in the R-
HepG2 cells incubated at 37°C and 43°C both at 5% CO2 1 hour, the mean of the 
fluorescent intensity of cells incubated at 37�C was 12.52 and the mean of the cells 
incubated at 43°C was 21.88. There was an increase in the accumulation of Dox into 
the cells when comparing with the hyperthermia and control cells (Fig. 3.33). 
In addition, when comparing between the accumulations of l|iM of 
LDL-Dox in the R-HepG2 cells incubated at 37°C and 43°C both at 5%C02 for 1 
hour, the mean of the fluorescent intensity of cells incubated at 37°C was 27.13 and 
the cells incubated at 43°C was 27.59. There was not a clear difference in the 
accumulation of LDL-Dox between the cells under 37�C and 4 3 � C (Fig. 3.34). 
The results indicated that hyperthermia could enhance Dox 
accumulated in the R-HepG2 cells that was comparable to the percentage cells 
survival with and without the hyperthermia treatment. But hyperthermia could not 
increase the accumulation of LDL-Dox in the cells. Therefore, the hyperthermia 
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could enhance the Dox accumulation in the cells in order to increase the cytotoxic 
effect of Dox. 
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Fig. 3.33. The quantitative analysis of doxorubicin accumulation in R-HepG2 cells. 
Cells at 1 X 10^  cells/well were seeded in 6-well plate for 48 hours. Cells were treated 
with 1|liM D o x for 1 hour at 37°C or 43°C. The accumulation of Dox was measured 
by flow cytometric analysis. The black line represented the control cells, i.e. cells 
incubated without Dox at 37°C. The red line represented the cells incubated with 
l^M Dox at 37°C. The green line represented the cells incubated with IjxM LDL-
Dox at 43�C. 
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Fig. 3.34. The quantitative analysis of low density lipoprotein-doxorubicin 
accumulated in R-HepG2 cells. Cells at 1 x 10^  cells/well were seeded in 6-well plate 
for 48 hours. Cells were treated with 1 |iM LDL-Dox for 1 hour at 37°C or 43°C. The 
accumulation of LDL-Dox was measured by flow cytometric analysis. The black line 
represented the control cells, i.e. cells incubated without LDL-Dox at 37°C. The red 
line represented the cells incubated with l|iM LDL-Dox at 37°C. The green line 
represented the cells incubated with 1 |j.M LDL-Dox at 43°C. 
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3.1.3.7.Confocal laser scanning microscopic (CLSM) studies on the 
accumulation of Dox and LDL-Dox in R-HepG2 cells with and without 
hyperthermia 
According to the result of flow cytometric analysis, when the R-
HepG2 cells incubated with Dox at 43 °C，the accumulation level of Dox in the cells 
was higher than Dox incubated at 37�C. When comparing the level of Dox 
accumulated in the cells incubated between 37°C and 43°C, it showed that the 
fluorescent intensity of Dox incubated at 43 °C was higher than that incubated at 
37°C. This result suggested that the intracellular level of Dox was enhanced by 
hyperthermia (Fig. 3.35). 
In addition, from the result of the confocal laser scanning microscopic 
images of LDL-Dox-treated cells at 37°C and 43°C, it showed that the fluorescent 
intensity of LDL-Dox incubated at 37�C was similar to that at 43�C. That means 
there was no significant difference between applying hyperthermia or not (Fig. 3.36). 
These results suggested that the combined treatment of Dox and 
hyperthermia could increase the intracellular level of Dox, but the intracellular level 
of LDL-Dox could not be enhanced by the hyperthermia and this result was 
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Fig. 3.35. The confocal laser scanning microscopic analysis on the accumulated level 
of Dox in R-HepG2 cells. Cell at 5 x cells were seeded on cover glass for 48 
hours. The cover glass was incubated with 5|LIM DOX for 1 hour at 37°C or 43°C. (A), 
Dox-treated R-HepG2 cells incubated at 37°C were scanned along the Z-axis for 
1 |Lim. (B), Dox-treated R-HepG2 cells incubated at 43°C were scanned along Z-axis 
for l|am. 
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Fig. 3.36. The confocal laser scanning microscopic analysis on the accumulated level 
o f LDL-Dox in R-HepG2 cells. Cells at 5 x lO'^  cells were seeded on cover glass for 
4 8 hours. The cover glass was incubated with 5)LIM L D L - D O X for 1 hour at 3 7 � C or 
43°C. (A), LDL-Dox-treated R-HepG2 cells incubated at 37°C were scanned along 
the Z-axis for Ijiim. (B), LDL-Dox-treated R-HepG2 cells incubated at 43°C were 
scanned along Z-axis for l|Lim. 
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3.1.3.8.Modulation of LDL receptors on R-HepG2 cells Up-
regulation of LDL receptors by Fructus Crataegus (FC) 
3.1.3.8.1.The comparsion of LDL receptor expression on R-HepG2 cells after 
Fructus Crataegus (FC) pre-treatment 
In R-HepG2 cells, when the cells treated with lipoprotein deficient 
serum (LPDS), the LDL receptor expression level was similar to that when the cells 
were treated with complete medium (control). Also the level of LDL receptor 
expression did not exhibit a very clear difference in cells between low density 
lipoprotein (LDL) treatment and LPDS treatment. This result showed that in R-
HepG2 cells, the LDL receptor level might not be down-regulated by the existence of 
LDL. As the cells under Fructus Crataegus (FC) treatment, the receptor expression 
level was also similar to that when the cells were under LPDS treatment. That means 
the FC could not up-regulate LDL receptor expression in R-HepG2 cells. When the 
cells co-treated with FC and LDL, the expression level was nearly equal to that of the 
cells treated with FC and LDL only. Therefore, there was no significant difference on 
the LDL receptor expression level among these treatments (Fig. 3.37). 
The result suggested that after FC pre-incubation, the LDL receptors 
expression level did not have a significant increase in R-HepG2 cells. Moreover, the 
LDL receptors expression was not suppressed by LDL. 
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Fig.3.37. The expression level of LDL receptors in various treatments in R-HepG2 
cells. Cells at 1 x 10^ cells/well were seeded in 6 well-plate overnight. Cells were 
treated with complete medium (CTL), lipoprotein deficient serum (LPDS), Fructus 
Crataegus (FC) in lipoprotein deficient serum, co-treatment of Fructus Crataegus 
and low density lipoprotein (FC and LDL) in lipoprotein deficient serum, low density 
lipoprotein (LDL) in lipoprotein deficient serum. The level of LDL receptor was 




3.1.3.8.2.The comparsion of the accumulation of LDL-Dox in R-HepG2 cells 
after Fructus Crataegus (FC) pre-treatment 
As shown in Fig. 3.38, in R-HepG2 cells, the accumulation of LDL-
Dox under complete medium (control) incubation was similar to that under LPDS 
incubation and the mean of the fluorescent intensity of cells was 21.10 and 22.27 
respectively. There was no significant increase of LDL-Dox accumulation in cells 
between complete medium and LPDS treatment. After the cells were treated with 
LDL, the accumulation of LDL-Dox was similar to that of the cells after the LPDS 
treatment that means the existence of LDL was not a factor to affect the LDL-Dox 
bound to the LDL-receptors because there was only a little bit decrease of LDL-Dox 
accumulation when compared that in cells after LPDS treatment. After the cells were 
treated with Fructus Crataegus (FC), the LDL-Dox accumulation was also similar to 
that of the cells treated with LPDS and the mean of the fluorescent intensity of cells 
under FC-treatment was 23.08 in which there was no clear intensity difference when 
compared with that of cells after LPDS treatment, also mostly of the fluorescent 
intensity of cells after FC-treated was due to the Dox fluorescent, not due to the FC 
itself. That means that FC could not enhance the accumulation of LDL-Dox in R-
HepG2 cells. As the cells were co-treated with FC and LDL, the LDL-Dox 
accumulation in the cells was nearly equal to that of the cells treated with FC. Thus 
the LDL-Dox accumulation in R-HepG2 cells was not affected by the pre-treatments. 
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These results suggested that the LDL-Dox accumulation in R-HepG2 
cells was not significantly increased between various treatments. This phenomenon 
was comparable to the results in LDL receptor expression level under different kinds 
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Fig. 3.38. The quantitative analysis of LDL-Dox accumulation in R-HepG2 cells. 
Cells at 1 X 10^  cells/well were seeded in 6-well plate overnight. Cells were treated 
with complete medium (control), lipoprotein deficient serum (LPDS), low density 
lipoprotein (LDL) in lipoprotein deficient serum, Fructus Crataegus (FC) in 
lipoprotein deficient serum and co-treatment of Fructus Crataegus and low density 
lipoprotein (FC and LDL) in lipoprotein deficient serum for 48 hours. After the pre-
treatment, l^iM LDL-Dox mixing in lipoprotein deficient serum was added for 1 
hour incubation. The accumulation of LDL-Dox was measured by flow cytometric 
analysis. The black line represented the control cells, which was not incubated with 
LDL-Dox. The red line represented the cells incubated with complete medium and 
1|LIM LDL-DOX. The green line represented the cells incubated with lipoprotein 
deficient serum (LPDS) and IfxM LDL-Dox. The blue line represented the cells 
incubated with low density lipoprotein (LDL) and 1 |uiM LDL-Dox. The purple line 
represented the cells incubated with Fructus Crataegus (FC) and 1 ^M LDL-Dox. 
The brown line represented the cells incubated with of Fructus Crataegus and low 
density lipoprotein (FC and LDL) and 1 ^M LDL-Dox. 
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3.1.3.8.3.Confocal laser scanning microscopic (CLSM) studies in the 
accumulation of LDL-Dox by Fructus Crataegus pre-treatment in R-
HepG2 cells 
In R-HepG2 cells, the confocal laser scanning microscopic images of 
LPDS-treated cells and complete medium-treated cells showed similar fluorescent 
intensity in the cells. This result suggested that the intracellular level of LDL-Dox 
under incubations of LPDS and complete medium was similar. After the cells were 
treated with LDL, there was not a clear difference of fluorescent intensity when 
comparing to the LPDS-treated cells, that means the existing LDL could not affect 
the intracellular level of LDL-Dox. When the cells were treated with FC, the 
fluorescent intensity of cells was similar to that of the cells treated with LPDS, i.e. 
the intracellular level of LDL-Dox could not be increased by FC pre-treatment and 
most of the fluorescent intensity of cells was due to the Dox fluorescent, but not due 
to the fluorescent of FC itself. As the cells were co-treated with FC and LDL, there 
was no significant difference in the fluorescent intensity of cells between FC and 
LDL treated only (Fig. 3.39 and Fig. 3.40) This phenomenon was comparable to the 
results in the LDL-Dox accumulation in the cells under different kinds of the 
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Fig. 3.39 The confocal laser scanning microscopic analysis on the accumulated level 
of LDL-Dox in R-HepG2 cells. Cells at 5 x cells were seeded on cover glass for 
4 8 hours. The cover glass was incubated with 5)LIM LDL-DOX for 1 hour at 37°C. (A)， 
complete medium (control)-treated R-HepG2 cells were scanned along the Z-axis for 
1 叫 (B) , lipoprotein deficient serum (LPDS>treated R-HepG2 cells were scanned 
along Z-axis for l|Lim. (C), Fructus Crataegus (FC) in LPDS-treated R-HepG2 cells 
were scanned along Z-axis for Ijiim. 
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Fig. 3.40. The confocal laser scanning microscopic analysis on the accumulated level 
of LDL-Dox in R-HepG2 cells. Cells at 5 x lO'^  cells were seeded on cover glass for 
48 hours. The cover glass was incubated with 5)aM LDL-Dox in LPDS for 1 hour at 
37�C. (A), co-treaed with Fructus Crataegus and low density liporotein (FC and 
LDL) in LPDS on R-HepG2 cells were scanned along the Z-axis for l)a,m. (B), low 
density lipoprotein in LPDS treated in R-HepG2 cells were scanned along Z-axis for 
l)Lim. 
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3.1.3.8.4.The comparison of cytotoxicity of combined treatment with LDL-Dox 
and Fructus Crataegus (FC) in R-HepG2 cells 
After the cells were treated with FC, the results showed that the 
protein expression level of LDL receptors and the accumulation of LDL-Dox in the 
cells did not exhibit a significant increase. So theoretically, the percentage of cell 
survival under the combined treatment of FC and LDL-Dox should be similar to that 
of the cells under the LDL-Dox treatment only. 
The R-HepG2 cells were pre-treated with FC in LPDS medium up to 
48 hours, then the cells were incubated at different concentrations of LDL-Dox 
ranging from 50)iM to 1.5626|^M under 37°C, 5% CO2 for 24 hours and the cells 
viability was determined by MTT assay. After the cells pre-treated with FC, the I C 5 0 
of LDL-Dox was 47.8|iM which was similar to that of the LDL-Dox treatment only, 
and the I C 5 0 of LDL-Dox after 24 hours treatment without FC-treated was 48^iM 
(Fig. 3.41). Moreover, there was not any cytotoxic effect of Img/ml FC on HepG2 
cells observed in the previous studies, thus the cytotoxicity of R-HepG2 cells 
determined in this assay was due to the cytotoxic effect of LDL-Dox. 
These results suggested that after FC pre-treatment, the LDL receptor 
expression level did not exhibit a significant increase, so the LDL-Dox accumulation 
in the cells was not increased and the cytotoxic effect of LDL-Dox was not enhanced 
by the FC pre-treatment. 
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The cytotoxicity of combined treatment with LDL-Dox and 
FC on R-HepG2 cells 
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Fig. 3.41. Effect of combined treatment with low density lipoprotein-doxorubicin and 
the pre-treatment of Fructus Crataegus (FC) on the survival of R-HepG2 cells. Cells 
at 5 X 10^ cells/well were seeded in a 96 wells plate overnight. Cells were treated 
with Img/ml of FC in lipoprotein deficient serum for 48 hours. After 48 hours, the 
cells were washed with IX PBS twice, then the cells were incubated at different 
concentration of LDL-Dox for further 24 hours. The percentage of cell survival was 
analyzed by MTT assay. In each well, 30|^1 MTT solution and 100^1 DMSO were 
added and the absorbance of the mixture was measured at wavelength 540nm. The % 
survival of each incubation was calculated as described in Material & Methods. 
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3.2. IN VIVO STUDIES 
3.2.1. The comparison of Dox and LDL-Dox on reducing the tumor 
sizes and weight in nude mice bearing R-HepG2 cells 
The effect of LDL-Dox on inhibiting the tumors was also investigated 
by measuring the tumor size and tumor weight when the mice were sacrificed. 
3.2.1.l.The comparison of Dox and LDL-Dox on reducing the tumor size in 
nude mice bearing R-HepG2 cells 
As shown in Fig. 3.42，after 4 weeks treatment, the tumor size of 
Img/kg Dox treated group was similar to that of the control group and there was no 
significant difference between the two groups (p�0.5) . But the mice treated with 
2mg/kg Dox showed a smaller tumor size when compared with that of the control 
group (p<0.001) and Img/kg Dox treated group (p<0.005). Also, the LDL-Dox 
treated group had a smaller size compared with that of the control group and Img/kg 
Dox treated group (p<0.001). But there was no significant difference between 
2mg/kg Dox treated group and Img/kg LDL-Dox treated group (p>0.5). This result 
shows that the antiproliferative effect of Img/kg LDL-Dox was greater than that of 
Img/kg Dox on R-HepG2 cells growing on the shoulder of the nude mice. 
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Fig. 3.42. Size of tumors after Dox and LDL-Dox treatment on R-HepG2 cells 
growing in nude mice. Nude mice were injected subcutaneously with 8 x 10^ of 
human resistance hepatoma R-HepG2 cells in the shoulder. After 2 days of 
inoculation, LDL-Dox and Dox at a dose of Img/kg as well as Dox at a dose of 
2mg/kg was injected intravenously on every other day. The sizes of tumor were 
measured after the end of the treatment. (*: p<0.001 compared with control group, **: 
P<0.005 compared with Img/kg Dox treated group, # : P<0.001 compared with 
Img/kg Dox treated group) 
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After 4 weeks treatment, the tumor sizes of R-HepG2 cells on nude 
mice under different treatments were shown at Figure 3.43，Figure 3.44，Figure 3.45, 
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Fig. 3.46. Size of tumors of nude mice bearing R-HepG2 cells treated with 2mg/kg 
Dox. Nude mice were injected subcutaneously with 8 x 10^  of human resistant 
hepatoma R-HepG2 cells in the shoulder. After 2 days of inoculation, Dox at a dose 
of 2mg/kg was injected intravenously on every other day until 4 weeks. 
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Fig. 3.47. Size of tumors of nude mice bearing R-HepG2 cells treated with Img/kg 
LDL-Dox. Nude mice were injected subcutaneously with 8 x 10^  of human resistant 
hepatoma R-HepG2 cells in the shoulder. After 2 days of inoculation, LDL-Dox at a 
dose of Img/kg was injected intravenously on every other day until 4 weeks. 
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3.2.1.2.The comparison of Dox and LDL-Dox on reducing the tumor weight in 
nude mice bearing R-HepG2 cells 
As shown in Fig. 3.48, after 4 weeks treatment, the tumor weight of 
Img/kg Dox treated group was similar to that of the control group and there was no 
significance different between the two groups. But the mice treated with 2mg/kg Dox 
showed a lower weight when compared with that of the control group (p<0.005) and 
Img/kg Dox treated group (p<0.05). Moreover, Img/kg LDL-Dox treated group had 
a lower weight when compared with that of the control group (p<0.005) and Img/kg 
Dox treated group (p<0.05). The tumor weight under 2mg/kg Dox treated group and 
Img/kg LDL-Dox treated group was similar. This result suggested that the 
antiproliferative effect of Img/kg LDL-Dox and 2mg/kg Dox was greater than that of 
Img/kg Dox on R-HepG2 cells growing on the shoulder of the nude mice. 
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Fig. 3.48. Weight of tumors of nude mice bearing R-HepG2 cells treated with Dox 
and LDL-Dox. Nude mice were injected subcutaneously with 8 x 10^ of human 
resistant hepatoma R-HepG2 cells in the shoulder. After 2 days of inoculation, LDL-
Dox and Dox at a dose of Img/kg and Dox and at dose of 2mg/kg Dox was injected 
intravenously on every other day. After 4 weeks treatment, tumors were removed on 
these ether anesthetized mice and weighted. (*: p<0.005 compared with control 
group，#: p<0.05 compared with Img/kg Dox-treated group) 
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3.2.2. Myocardial injury measured by Lactate dehydrogenase (LDH) 
activity in nude mice bearing R-HepG2 cells treated with Dox 
and LDL-Dox 
Lactate dehydrogenase (LDH) catalyzes the interconversion of lactate 
and pyruvate. LDH plasma activity in plasma is significantly elevated during 
myocardial injury. Plasma of different groups of mice was collected as described in 
the Methods section. 
In the investigation, one group of nude mice did not receive 
subcutaneous injection of the R-HepG2 cells was called "none group". As shown in 
Fig. 3.49, the LDH plasma activity in control group, which was injected with saline, 
was similar to that of the none group and the mean of LDH activity in none group 
and the control group were 37.47 U/L and 41.30 U/L respectively, without 
significant difference. Moreover, the LDH plasma activity was higher in the Dox-
treated group when compared with that of the control group after 4 weeks treatment 
(p<0.05). The mean of LDH plasma activity in Img/kg Dox-treated group was 89.13 
U/L and 2mg/kg Dox-treated group was 99.85 U/L. Also, the LDH plasma activity in 
high dose of Dox treated group was higher than that in low dose of Dox treated 
group. On the other hand, LDH plasma activity in LDL-Dox treated group was 
similar to that in the control group. The mean LDH plasma activity in LDL-Dox 
treated group was 36.80 U/L while that for the control group was 41.30 U/L. 
Moreover, the LDH plasma activity in LDL-Dox treated group was lower than that in 
the Dox treated group (p<0.05). 
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This result indicated that no heart damage was observed in LDL-Dox 
treated group. In addition, the level of heart damage in Dox-treated group was higher 
than that in LDL-Dox treated group. Also, the level of heart damage was dose-
dependent of Dox, ie. the higher dosage of Dox used, the higher level of heart 
damage could be observed. 
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Fig. 3.49. Cardiotoxic effects of Dox and LDL-Dox in nude mice bearing R-HepG2 
cells. Nude mice were injected subcutaneously with 8 x 10^ of human resistant 
hepatoma R-HepG2 cells in the shoulder. After 2 days of inoculation, LDL-Dox and 
Dox at a dose of Img/kg and Dox at dose 2mg/kg was injected intravenously on 
every other day. After 4 weeks treatment, a heparinized blood sample was collected 
from ether anesthetized mice by cardiac puncture. The blood was then centriftiged at 
lOOOx g for 15 minutes. The plasma obtained from the upper clear fraction was then 
analyzed for the LDH plasma activity. (*: p<0.05 compared with none group, #. 
p<0.05 compared with control group, **: p<0.05 compared with Img/kg Dox treated 
group and 2mg/kg Dox treated group) 
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3.2.3. Myocardial injury measured by Creatine kinase (CK) activity 
in nude mice bearing R-HepG2 cells treated with Dox and 
LDL-Dox 
Creatine kinase (CK) is primarily located in skeletal muscle, brain 
tissue and heart muscle. Damage to these tissues results in the release of increased 
levels of creatine kinase into blood. Cardiac muscle injury following myocardial 
infarction results in a rise in serum CK activity. Therefore, measurement of serum 
CK activity is one of the useful diagnostic markers to detect myocardial injury. 
Plasma samples of different groups of mice were collected as described in Methods. 
There was no significant difference between the none group and the 
control group in CK plasma activity. The CK plasma activity was higher in the Dox-
treated group when compared with that of the control group after 4 weeks treatment. 
The mean CK plasma activity of Img/kg Dox-treated group and 2mg/kg Dox-treated 
group were 485.77 U/L and 496.37 U/L respectively. On the other hand, CK plasma 
activity in LDL-Dox treated group was similar to that of the control group. The mean 
CK plasma activity in LDL-Dox treated group was 396.20 U/L while that for the 
control group was 394.69 U/L. Moreover, the CK plasma activity in LDL-Dox 
treated group was lower than that in Dox-treated group (Fig. 3.49). 
This result indicates that no heart damage was observed in LDL-Dox 
treated group. In addition, the heart damage in Dox-treated group was higher than 
that in LDL-Dox treated group. The level of heart damage was dose-dependent, ie. 
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Fig. 3.49. Cardiotoxic effects of Dox and LDL-Dox in nude mice bearing R-HepG2 
cells. Nude mice were injected subcutaneously with 8 x 10^ of human resistant 
hepatoma R-HepG2 cells in the shoulder. After 2 days of inoculation, LDL-Dox and 
Dox at a dose of Img/kg and Dox at a dose of 2mg/kg was injected intravenously on 
every other day. After 4 weeks treatment, a heparinized blood sample was collected 
from ether anesthetized mice by cardiac puncture. The blood was then centrifuged at 
lOOOx g for 15 minutes. The plasma obtained from the upper clear fraction was then 
analyzed for the CK plasma activity. 
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3.2.4. Histological studies of heart of nude mice bearing R-HepG2 
cells treated with Dox and LDL-Dox 
3.2.4.1.Heart section of nude mice 
The heart section from nude mice was observed under light 
microscope. In this group (none group), the nude mice did not receive any R-HepG2. 
In this heart section of none group, the pattern of mycocardial muscle alignment and 
the location of muscle cell nuclei could be observed. It was shown that the 
mycocardial filament were well organized, smooth and tightly packed (Fig. 3.50). 
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Fig. 3.50. Heart section of nude mice without subcutaneously of R-HepG2 cells 
(None group) 
Magnification: 2.5 x 40 x 1 x 4 = 400x 
Sample: ventricular wall portion 
Nude mice did not receive any human resistant hepatoma R-HepG2 cells. During the 
treatment, the mice did not have any injection. After 4 weeks treatment, the mice 
were sacrificed by cervical dislocation and the hearts were quickly removed for 
histological slide preparation. 
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3.2.4.2.Heart section of nude mice bearing R-HepG2 cells 
The heart section from the tumor bearing nude mice was observed 
under light microscope. It was obtained from the control group in which no Dox and 
LDL-Dox was injected to the mice but only saline was injected. In this heart section 
of control group, the pattern of myocardial muscle alignment and the location of 
muscle cell nuclei could be observed. It was found that the myocardial filaments 
were well organized, smooth and tightly packed. Moreover, there was no clear 
difference in the pattern of mycocardial filaments between the none group and the 
control group (Fig. 3.51). 
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Fig. 3.51. Heart section ofR-HepG2 bearing nude mice (Control group) 
Magnification: 2.5 x 40 x 1 x 4 = 400x 
Sample: ventricular wall portion 
Nude mice were injected subcutaneously with 8 x 10^ of human resistant hepatoma 
R-HepG2 cells in the shoulder. After two days of inoculation, saline was injected 
intravenously on every other day. After 4 weeks treatment, the mice were sacrificed 
by cervical dislocation and the hearts were quickly removed for histological slide 
preparation. 
- 1 4 9 -
RESULTS 
3.2.4.3.Heart section of Img/kg Dox treated nude mice bearing R-HepG2 cells 
The heart section from the Img/kg Dox treated nude mice bearing R-
HepG2 cells was observed under light microscope. Dox at a dose of Img/kg was 
injected to these mice intravenously on every other day. It was found that the 
organization of myocardial filaments was disrupted by Dox and vacuolization was 
found when compared with control group (Fig. 3.52). 
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Fig. 3.52. Heart section of R-HepG2 bearing nude mice treated with Img/kg Dox 
Magnification: 2.5 x 4 0 x 1 x 4 = 400x 
Sample: ventricular wall portion 
Nude mice were injected subcutaneously with 8 x 10%f human resistant hepatoma 
R-H叩G2 cells in the shoulder. After 2 days of inoculation, Dox at a dose of Img/kg 
was injected intravenously on every other day. After 4 weeks treatment the mice 
were sacrificed by cervical dislocation and the hearts were quickly removed for 




3.2.4.4.Heart section of 2mg/kg Dox treated nude mice bearing R-HepG2 cells 
The heart section from the 2mg/kg Dox treated nude mice bearing R-
HepG2 cells was observed under light microscope. Dox at a dose of 2mg/kg was 
injected to these mice intravenously on every other day. It was found that the 
organization of myocardial filaments was disrupted by Dox and vacuolization was 
found when compared with control group. Moreover, the disruption of filament 




Fig. 3.53. Heart section of R-HepG2 bearing nude mice treated with 2mg/kg Dox 
Magnification: 2.5 x40 x 1 x 4 = 400x 
Sample: ventricular wall portion 
Nude mice were injected subcutaneously with 8 x 10^ of human resistant hepatoma 
R-HepG2 cells in the shoulder. After two days of inoculation, Dox at a dose of 
2mg/kg was injected intravenously on every other day. After 4 weeks treatment, the 
mice were sacrificed by cervical dislocation and the hearts were quickly removed for 
histological slide preparation. A: the disrupted myocardial filament; B: 
vancuolization. ‘ 
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3.2.4.5.Heart section of Img/kg LDL-Dox treated nude mice bearing R-HepG2 
cells 
The heart section from the Img/kg LDL-Dox treated nude mice 
bearing R-HepG2 cells was observed under light microscope. LDL-Dox at a dose of 
Img/kg was injected to these mice intravenously on every other day. There was no 
significant disruption of myocardial filaments and vacuolization found on the heart 
section when compared with control group (Fig. 3.54). 
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Fig. 3.54. Heart section of R-HepG2 bearing nude mice treated with Img/kg LDL-
Dox 
Magnification: 2.5 x 4 0 x 1 x 4 = 400x 
Sample: ventricular wall portion 
Nude mice were injected subcutaneously with 8 x 10%f human resistant hepatoma 
R-HepG2 cells in the shoulder. After two days of inoculation, LDL-Dox at a dose of 
Img/kg was injected intravenously on every other day. After 4 weeks treatment, the 
mice were sacrificed by cervical dislocation and the hearts were quickly removed for 
histological slide preparation. 
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CHAPTER 4 : DISCUSSION 
4.1. IN VITRO STUDIES 
4.1.1. The cytotoxicity of Dox and LDL-Dox on HepG2 cells and R-
HepG2 cells 
Results from other workers suggested that the expression level of 
LDL-receptors on tumor cells was higher than that on normal cells because more 
LDL would be taken up in tumor cells than that of normal cells for membrane 
synthesis. Moreover, the patients bearing various cancers are usually found to suffer 
from hypocholesterolemia and hypolipoproteinemia (Alexopoulos et al” 1987). 
Regarding to these reasons, LDL is proposed as a target carrier to deliver the 
anticancer drug to the target tumor cells. This strategy could increase the selectivity 
of the anticancer drugs to the cancer cells and reduce the adverse side effects to the 
normal cells. 
The results from the quantitative analyses in the accumulation of 
doxorubicin (Dox) and low density lipoprotein-doxorubicin (LDL-Dox) in HepG2 
cells and R-HepG2 cells showed that the LDL-Dox accumulated in the cells was 
higher than that of free Dox, especially in R-HepG2 cells. These results were 
consistent with the current literatures studies, i.e. the higher amount of LDL-Dox 
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accumulated in tumor cells was due to the higher expression level of LDL receptors 
on their cell membranes. 
When comparing the cytotoxic effect of free Dox and LDL-Dox on 
HepG2 cells and R-HepG2 cells, the results showed that the effect was time-
dependent, i.e. the longer drug incubation time, the lower percentage cell survival 
was observed, as well as dose-dependent, i.e. the higher concentration of drug used, 
the lower percentage survival was observed. In HepG2 cells, the cytotoxic effect of 
free Dox was higher than that of LDL-Dox but vice versa in R-HepG2 cells. This 
might imply that in HepG2 cells, Dox might need a longer time to release from the 
LDL-complex, so the cytotoxic effect of Dox in LDL-Dox was reduced. On the other 
hand，in R-HepG2 cells, since the size of LDL with diameter of22nm (Krieger et al” 
1979)，is bigger than the pore size of P-glycoprotein (P-gp) whose diameter is Snm, it 
is difficult for P-gp to bind LDL-Dox and to pump it out. In the case of free Dox, our 
data indicated that free Dox would be pumped out by P-gp. So the antiproliferative 
effect of LDL-Dox on R-HepG2 cells was higher than that of free Dox. 
4.1.2. The combined treatment on HepG2 cells and R-HepG2 cells 
Since prolonged chemotherapy would induce cancer cells developing 
into resistance to a spectrum of anticancer drugs, the combined treatment would be 
used to enhance the antiproliferative effects of anticancer drugs in these resistant 
cancer cells as well as decrease the side effects on normal cells. Two combined 
treatments, namely hyperthermia to enhance the cell membrane permeability, alter 
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drug transport activity and the alter cell metabolism (Leunig et al., 1992)) and a 
Traditional Chinese Medicine, Fructus Craegtus to modulate the LDL receptors, 
were used to enhance the cytotoxicity of Dox and LDL-Dox on cancer cells. 
For the free Dox and hyperthermia treatment, after HepG2 cells and 
R-HepG2 cells were incubated with free Dox at 43°C, the intracellular level of free 
Dox was increased. Moreover, the cytotxic effect of free Dox combined with 
hyperthermia on HepG2 cells was higher than that of free Dox incubated at 37�C. It 
may be because mild heat would increase the cell membrane permeability and alter 
the drug transport activity (Leunig et al., 1992). Thus the uptake of free Dox could 
be enhanced by the cancer cells when combined with hyperthermia and lead to more 
cytotoxicity on the cancer cells. 
When HepG2 cells and R-HepG2 cells were incubated with LDL-Dox 
at 43°C，the intracellular level of LDL-Dox was similar to that when the cells were 
incubated with LDL-Dox at 37°C. However, the cytotoxic effect of LDL-Dox 
combined with hyperthermia was higher than that of LDL-Dox treatment only. The 
intracellular level of LDL-Dox was not in parallel to the degree of the cytotoxic 
effect of LDL-Dox when combined with hyperthermia. This might imply that 
hyperthermia could not enhance the uptake of LDL-Dox, but it might affect the 
metabolic rate of LDL-Dox in the cells (Leunig et al., 1992), such as increasing the 
rate of LDL degradation. Therefore, the amount of Dox released from LDL-complex 
was increased at 43°C when compared with that of the cells at 3 7 � C and lead to as 
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increase of the cytotoxic effect of LDL-Dox when combined with the hyperthermia 
treatment. 
A Traditional Chinese Medicine, Fructus Crataegus (FC), was also 
used as a combined treatment in present study to increase the antiproliferative effect 
of LDL-Dox on the tumor cells. Since the components of FC would reduce the serum 
cholesterol, especially LDL, they may increase the cell expression level of LDL 
receptors in cells. After the pre-treatment of FC on HepG2 cells, the cytotoxic effect 
of LDL-Dox was increased when compared with that of the cells treated with LDL-
Dox only. Moreover, there was about 15-fold increase of cytotoxic effect of LDL-
Dox after FC pre-treatment when compared with that of the LDL-Dox treatment 
only. This result implied that FC would enhance the LDL receptors on HepG2 cells 
or increase the binding activity of LDL-Dox to the LDL receptors in order to 
increase the accumulation of LDL-Dox in the cells and lead to enhance the cytotoxic 
effect of LDL-Dox. But in R-HepG2 cells, the cytotoxic effect of LDL-Dox could 
not be increased by the pre-treatment of FC. The mechanism is not known. 
4.1.3. The modulation of LDL-R expression 
Although the number of LDL receptors on tumor cells were higher 
than that on normal cells, up-regulation of LDL receptors on tumor cells was also an 
important strategy when applying LDL-Dox to treat tumor cells. It is because the up-
regulation of LDL receptors on tumor cells could increase the specificity of LDL-
Dox to the target tumor cells in order to decrease the adverse side effect to the 
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normal cells. Current studies showed that taurine could enhance the LDL receptor 
activity (Zouhair et al” 1987)，insulin could affect the synthesis of the LDL receptors 
(Wade et al, 1989). In this project, the Traditional Chinese Medicine, Fructus 
Crataegus (FC), was used to study the possiblity of the up-regulation of LDL 
receptors on tumor cells. 
After the treatment of FC, the expression level of LDL receptors on 
HepG2 cells was elevated, but not on R-HepG2 cells when compared with that on 
these cells treated with lipoprotein deficient serum only. Moreover, in HepG2 cells 
the power of up-regulation of the expression level of LDL receptors by FC was 
higher than that of LDL-mediated down-regulation of expression level of LDL 
receptors on tumor cells. It was because when the HepG2 cells were co-treated with 
LDL and FC, the expression level of LDL receptors was higher than that of the cells 
treated with LDL only. Thus, the FC could compensate part of the down-regulation 
of LDL receptors induced by LDL. But the density of LDL receptors on R-HepG2 
cells could not be elevated by FC, and it also could not be down-regulated by LDL. 
The reasons might be that the density of LDL receptors on resistant cells had been 
saturated, so they were not easily affected by the pre-treatment of FC that was done 
in order to promote the expression level of LDL receptors. The amount of LDL 
receptors also could not be down-regulated by LDL because the growth rate of 
resistant cells was faster than that of the parental cancer cells, so the resistant cells 
required more LDL for membrane synthesis. 
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The up-regulation of FC in the LDL receptors expression level on 
HepG2 cells caused an increase of the accumulation of LDL-Dox in the cells 
resulting in an increase of the cytotoxic effect of LDL-Dox in these cells. Moreover, 
the accumulation of LDL-Dox in the cells was decreased when the cells were treated 
with LDL. It was because most of the LDL receptors might be bound by LDL or the 
LDL might down-regulate the expression of LDL receptors. The accumulation of 
LDL-Dox under FC and LDL treatment was lower than that observed under FC pre-
treatment only, but higher than that observed under LDL pre-treatment only. The 
reasons might be that LDL might bind to a part of LDL receptors or diminish a part 
of LDL receptors expression, so the intracellular level of LDL-Dox was decreased. 
These results were consistent with the results from the protein expression level of 
LDL receptors on HepG2 cells after various pre-treatments. In R-HepG2 cells, since 
the amount of LDL receptors on resistant cells was saturated, so the accumulation of 
LDL-Dox in the resistant cells was not affected by various treatments. This means 
that when the resistant cells were incubated with or without FC, LDL or FC and LDL, 
the intracellular level of LDL-Dox was the same as that when the resistant cells were 
incubated with lipoprotein deficient serum only. These results were consistent with 
the results from the protein expression level of LDL receptors on R-HepG2 cells 
after various pre-treatments with FC. In addition, after the R-HepG2 cells were pre-
incubated with FC, the cytotoxic effect of LDL-Dox was not increased when 
compared with the results when the cells were treated with LDL-Dox only. 
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4.2 IN VIVO STUDIES 
It was crucial to demonstrate that LDL-Dox could work as a target 
carrier to the anticancer drugs and had a better selectivity than free Dox when 
treating tumor bearing nude mice. To compare the antiproliferative effect of free Dox 
and LDL-Dox, the tumor size and weight would be measured during different 
treatments, and to compare the cardiotoxic effect of free Dox and LDL-Dox, the 
plasma levels of lactate dehydrogenase (LDH) and plasma creatine kinase (CK) 
would be measured. Moreover, the histological studies would be used as an indicator 
of the level of heart damage. 
Results on parental HepG2 cells bearing nude mice in previous 
studies showed that the anti-proliferative effect of Img/kg LDL-Dox was similar to 
that of Img/kg free Dox on the tumor bearing nude mice, i.e. the tumor weight and 
tumor size in Img/kg LDL-Dox treated group were similar to those in Img/kg free 
Dox treated group. Moreover, in the histogical studies in heart section of Img/kg free 
Dox treated group showed that vacuolization, dilation and disruption of myofibrils 
arrangement could be observed when compared with the control group which only 
injected saline. However, the Img/kg LDL-Dox treated group did not exhibit any 
heart damage when compared with the control group. The studies on plasma lactate 
dehydrogenase (LDH) showed that the Dox-treated group exhibited higher plasma 
LDH activity when compared with the control group. In contrast, LDL-Dox treated 
group exhibited similar plasma LDH activity when compared with control group. 
These results indicated that LDL-Dox would exhibit a similar anti-proliferative effect 
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on parental HepG2 cells bearing nude mice and reduce the cardiac toxicity induced 
by free Dox (Chu et al., in press). 
The studies on the tumor size and weight in R-HepG2 bearing nude 
mice in present studies showed that the tumor size and weight in Img/kg Dox-treated 
group was similar to that in the control group. But the tumor size and weight in 
2mg/kg Dox-treated group was lower than that in control group. These results 
showed that in R-HepG2 cells bearing nude mice, the lower concentration of Dox did 
not exhibit any antitumor effect because the existence of P-glycoprotein in the 
resistant cells would decrease the concentration of free Dox in the target cells. 
Moreover, when higher dose of Dox was used, although the P-glycoprotein would 
pump out free Dox, by proportion, the concentration of free Dox in the target cells 
was higher than that when lower dose of Dox was used. Therefore, the 
antiproliferative effect of 2mg/kg Dox treatment was higher than that of Img/kg Dox 
treatment. These results were consistent with those from the percentage survival of 
R-HepG2 cells on Dox treatment because the I C 5 0 of free Dox for 48 hours treatment 
was 3 0 0 j L i M . In addition, the tumor size and weight in Img/kg LDL-Dox treated 
group was lower than that in control group and Img/kg Dox-treated group. These 
results implied that the antiproliferative effect of Img/kg LDL-Dox treatment was 
higher than that of Img/kg Dox treatment. Moreover, the size and weight of tumor in 
Img/kg LDL-Dox treated group was similar to that in 2mg/kg Dox treated group. 
This result showed that the antitumor effect of LDL-Dox was higher than that of free 
Dox because after the Dox was coupled into the LDL, the dose of Dox used in LDL-
Dox was lower than that of free Dox used. This implied that after Dox was coupled 
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into LDL, the LDL-Dox so formed was not easily to be pumped out by the P_ 
glycoprotein because of the size of LDL was larger than the pore size of P-
glycoprotein. This result was consistent to that from the percentage of cells survival 
on free Dox and LDL-Dox treatments, i.e. the cytotoxic effect of LDL-Dox, in which 
I C 5 0 was 1 5 | i M for 48 hours, was higher than that of free Dox, in which I C 5 0 was 
3 0 0 j L i M for 48 hours, on the resistant cells. These results also demonstrated that the 
targeted effect of LDL-complex to the tumor cells because the lower dosage of LDL-
Dox could exhibit the same antitumor effect on the tumor-bearing mice treated at 
higher dosage of free Dox. 
Reports from the literatures showed that the major side effects of Dox 
were cardiomyopathy and congestive heart failure (Singal et al.’ 1997). The results 
from histological studies of heart section showed that in the nude mice which did not 
receive subcutaneously of R-HepG2 cells (none group), the mycocardial filament 
were well organized and tightly packed and this phenomenon was also observed in 
the control tumor-bearing mice group which were only injected with normal saline 
during the 4 weeks treatment. This result implied that saline would not affect the 
organization of mycocardial filament. But in the Dox treated groups, including 
treatment of Img/kg and 2mg/kg free Dox, the vacuolization, dilation and disruption 
of myofibrils arrangement in the heart sections could be observed in the R-HepG2 
bearing nude mice when compared to the control group. This result shows that free 
Dox could induce cardiac toxicity. In contrast, LDL-Dox treated mice showed that 
there was no clear vacuolization, dilation and disruption of myofibrils arrangement in 
the heart section when compared to that of the control group. Thus this result implies 
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that LDL-Dox exerted less cardiac toxicity than free Dox, and Img/kg LDL-Dox 
treatment exhibited similar antiproliferative effect of 2mg/kg free Dox treatment. 
The studies on plasma lactate dehydrogenase (LDH) activity and 
creatine kinase (CK) activity in nude mice would also demonstrate the level of heart 
damage induced by different kind of treatments. It was because when heart damage 
took place, the level of plasma LDH and CK would significantly increase. The 
plasma LDH activity in none group was similar to that in the saline group, suggesting 
that saline did not induce the cardiac toxicity effect. After the tumor bearing mice 
were treated with free Dox, at high and low dose of Dox, the plasma LDH activity in 
both treated groups were higher when compared with that of the control group. 
Moreover, the plasma LDH activity at high dose treatment was higher than that at 
low dose treatment, i.e. the higher concentration of free Dox used, the higher degree 
of cardiac toxicity would result. In contrast, the tumor bearing mice treated with 
Img/kg LDL-Dox showed a plasma LDH activity similar to that of the control group. 
This result suggested that the LDL-Dox-induced heart damage was much lower than 
that induced by free Dox. These results were consistent to those from the histological 
studies of heart section, i.e. free Dox could induce cardiac toxicity but LDL-Dox 
treatment could not induce any cardic toxicity. 
For the measurement of plasma CK activity in different groups, the 
none group and control group showed a similar plasma CK activity. In addition, in 
LDL-Dox treated tumor bearing mice, the plasma CK activity was similar to that of 
the control group. Thus, this result indicated that the LDL-Dox exerted less cardiac 
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toxicity. These results were consistent to the results from the plasma LDH activity 
measurement. In contrast, the levels of plasma CK activity in Dox-treated group, 
treated with Img/kg free Dox or 2mg/kg free Dox, were both higher when compared 
with those of the control group. Also the plasma CK activity in group with high dose 
free Dox treatment was higher than that in low dose free Dox treatment. This result 
means the heart damage was induced by free Dox treatment and the level of heart 
damage was dose-dependent, i.e. the higher concentration of Dox used, the higher 
level of cardiac toxic effect. This result was also consistent to the result from the 
plasma LDH activity measurement. 
The aforesaid results gave more solid evidence on the reduction of the 
cardiac toxic side effect by using LDL as Dox carrier. In addition, it showed that 
lower dose of LDL-Dox could have the similar antiproliferative effect as high dose 
free Dox treatment in R-HepG2 bearing mice in vivo, that means LDL-Dox could 
circumvent multidrug resistance in these resistant cells. 
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CHAPTER 5 : CONCLUSION 
5.1. CONCLUSION 
5.1.1. In vitro studies 
In the present studies, our results have demonstrated that low density 
lipoprotein (LDL) can work as a drug carrier to the target tumor cells. The antitumor 
drug, doxorubicin (Dox) was coupled with the LDL without altering the structure of 
LDL. Moreover, the intracellular level of LDL-Dox in HepG2 cells and R-HepG2 
cells was found to be higher than that of free Dox. Although the cytotoxic effect of 
LDL-Dox was lower in the HepG2 cells when compared with the free Dox at the 
same dose, its cytotoxicity was higher in R-HepG2 cells when compared with the 
free Dox in vitro. It shows that LDL-Dox is able to circumvent the resistant cells 
because the size of LDL is bigger than the pore of P-glycoprotein, so it is difficult for 
P-glycoprotein to pump the LDL out of the cells. 
In addition, modulation of LDL receptors on tumor cells is also 
important because it can increase the population of LDL receptors on tumor cells in 
order to increase the accumulation of LDL-Dox in the cells. The studies found that a 
Traditional Chinese Medicine, Fructus Crataegus (FC), can elevate the expression 
level of LDL receptors on HepG2 cells in order to increase the intracellular level of 
LDL-Dox resulting in increase of the cytotoxic effect of LDL-Dox on HepG2 cells 
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when compared with that of the LDL-Dox treatment only. Moreover, the power of 
FC in elevating the LDL receptors on HepG2 cells is higher than that of LDL down-
regulating the LDL receptors on tumor cells. In contrast, the Traditional Chinese 
Medicine, FC, and the existence of LDL did not affect the density of LDL receptors 
on R-HepG2 cells and the intracellular level of LDL-Dox in the cells. So these 
results suggest that the amount of LDL receptors on the resistant cells were not 
affected by these two factors. This difference is because the growth rate of R-HepG2 
cells is faster than that of parental HepG2 cells, so the amount of LDL used for 
membrane synthesis is more than that of the parental cells and the LDL receptors on 
resistant cells is higher. The conclusions of the current studies are that FC induces 
the LDL receptors activity on parental HepG2 cells but not on R-HepG2 cells. 
Therefore，parental cells can accumulate more LDL-Dox and lead to higher 
cytotoxicity. 
Hyperthermia is another strategy to increase the efficiency of free 
Dox and LDL-Dox. In HepG2 cells and R-HepG2 cells, as the free Dox combined 
with hyperthermia, the intracellular level of free Dox is increased. It is because 
hyperthermia is able to increase the cell membrane permeability and then lead to 
more cytotoxicity. Although in HepG2 cells and R-HepG2 cells, the accumulation of 
LDL-Dox cannot be enhanced by hyperthermia, the cytotoxic effect of LDL-Dox is 
increased when combined with hyperthermia. It is because heat may alter the cell 




5.1.2. In vivo studies 
It is important to demonstrate that LDL can serve as a drug carrier to 
the target tumor cells in the clinical trail. The nude mice bearing R-HepG2 cells were 
treated with saline, Img/kg Dox，2mg/kg Dox and Img/kg LDL-Dox. After four 
weeks treatment, the tumor size and weight in descending order is as follows: saline, 
Img/kg Dox, 2mg/kg Dox, Img/kg LDL-Dox. This result indicate that lower 
concentration of free Dox does not have any significant antiproliferative effect in the 
R-HepG2 bearing nude mice. But in the higher dose of free Dox, its antiproliferative 
effect is similar to that of Img/kg LDL-Dox treatment. It implies that the antitumor 
effect of LDL-Dox is higher than that of the free Dox, i.e. the low dose of LDL-Dox 
used has the same antiproliferative effect as that of a higher dose of free Dox used. 
By observing the histological section of hearts in R-HepG2 bearing 
nude mice, the pattern of myocardial filament in none group and control group is the 
same which indicated that saline does not cause the damage of heart. Moreover, only 
the Dox treatment，no matter at Img/kg free Dox or 2mg/kg free Dox, caused the 
disruption and vacuolization of myocardial filament. But this damage is not found in 
mice treated with LDL-Dox. In addition, the plasma LDH activity and plasma CK 
activity was higher in the Dox-treated mice when compared with those of LDL-Dox 
treated mice and the control group. These results further prove that LDL-Dox does 
not exert severe cardiac toxicity like the free Dox. Furthermore, the antiproliferative 
effect of LDL-Dox is similar to that of the higher dose of free Dox treatment on R-
HepG2 bearing nude mice. 
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5.2. FUTURE PROSPECTIVE 
Although LDL-Dox has better selectivity towards tumor cells and 
decreases the side effect, it is still important to improve the antitumor effect of LDL-
Dox. According to the in vitro result, it shows that the Traditional Chinese Medicine, 
Fructus Crataegus (FC), can elevate the LDL receptor expression, so this effect 
would need to be studied concerning the effects of FC on the regulation of the LDL 
receptors activity in HepG2 bearing nude mice. Moreover, it is important to prove 
that FC only can induce the expression level of LDL receptors in tumor cells, but not 
in normal tissues. 
In addition, the combined treatment of hyperthermia and LDL-Dox 
could increase the release of free Dox from LDL-complex in the tumor (HepG2 cells 
and R-HepG2 cells) bearing nude mice in order to increase the antiproliferative 
effect of LDL-Dox. Since the combined treatment of hyperthermia and free Dox 
could increase the uptake by the tumor cells, this strategy need to be proven in the 
tumor bearing nude mice. 
Since the model in the current studies is to use nude mice with the 
injection of tumor cells subcutaneously, it is important to create a model in which the 
liver cancer cells are located in the liver, which is more clinically relevant to 
investigation of the LDL-Dox cytotoxicity on liver cancer. In that model the tumor 
cells may be implanted into the spleen of nude mice in which the cells can be 




Last but not least, there is a limitation in the concentration of the 
LDL-Dox preparation. The method used in the current studies is about SOO^M at 
maximum. This maximum concentration limits the dose of treatment to tumor 
bearing mice at a lower concentration. Therefore we need to enhance the coupling 
efficiency in order to use a higher dose of drug for the investigation to examine 
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